FORM PTO-1390 (Modified) (REV 11-98) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)
113.1007	09/581005

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/EP98/08696	December 11, 1998	December 11, 1997

TITLE OF INVENTION

TCG METHOD FOR INDUCTING TARGETED SOMATIC TRANSGENESIS

APPLICANT(S) FOR DO/EO/US

VON EICHEL-STREIBER, Christoph, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☒ has been transmitted by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
   b. ☐ have been transmitted by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

- **Letter re: Priority**
- **Postcard**
- **Genetic Sequence Submission [Computer Readable Copy; Paper Copy; and Statement Verifying Identical Paper and Computer Readable Copy]**
- **Submission of Declaration of Deposit with Deposit Receipts**
- **Statement Claiming Small Entity Status**

526 Rec'd PCT/PTO 06 JUN 2000

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
09/581005	PCT/EP98/08696	113.1007

21. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO and International Search Report not prepared by the EPO or JPO **$970.00**	
☒	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but Internation Search Report prepared by the EPO or JPO **$840.00**	
☐	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$690.00**	
☐	International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$670.00**	
☐	International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) **$96.00**	
	ENTER APPROPRIATE BASIC FEE AMOUNT =	**$840.00**
Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☒ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).		**$130.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	29 - 20 =	9	x $18.00	**$162.00**	
Independent claims	2 - 3 =	0	x $78.00	**$0.00**	
Multiple Dependent Claims **(check if applicable)**.			☐	**$0.00**	
	TOTAL OF ABOVE CALCULATIONS =			**$1,132.00**	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) **(check if applicable)**. ☒				**$566.00**	
	SUBTOTAL =			**$566.00**	
Processing fee of **$130.00** for furnishing the English translation later than ☒ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +				**$130.00**	
	TOTAL NATIONAL FEE =			**$696.00**	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☐				**$0.00**	
	TOTAL FEES ENCLOSED =			**$696.00**	
				Amount to be: refunded	$
				charged	$

☒ A check in the amount of **$696.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. in the amount of to cover the above fees.
A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-0552** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Clifford M. Davidson, Esq.
DAVIDSON, DAVIDSON & KAPPEL
1140 Avenue of the Americas 15th Floor
New York, New York 10036
Tel: (212) 997-1028
Fax: (212) 997-1037

SIGNATURE

William C. Gehris
NAME

38,156
REGISTRATION NUMBER

June 6, 2000
DATE

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(f) & 1.27(b))—INDEPENDENT INVENTOR	Docket Number (Optional) 113.1007

Applicant, Patentee, or Identifier: Christoph VON EICHEL-STREIBER, et al.

Application or Patent No.: PCT/EP98/08696

Filed or Issued: December 11, 1998

Title: TGC METHOD FOR INDUCTING TARGETED SOMATIC TRANSGENESIS

As a below named inventor, I hereby state that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees to the Patent and Trademark Office described in:

- ☐ the specification filed herewith with title as listed above.
- ☒ the application identified above.
- ☐ the patent identified above.

I have not assigned, granted, conveyed, or licensed, and am under no obligation under contract or law to assign, grant, convey, or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ No such person, concern, or organization exists.
- ☐ Each such person, concern, or organization is listed below.

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

C. VON EICHEL-STREIBER	T. CHAKRABORTY	
NAME OF INVENTOR	NAME OF INVENTOR	NAME OF INVENTOR
Signature of inventor	Signature of inventor	Signature of inventor
24/05/00	24/5/2000	
Date	Date	Date

113.1007

UNITED STATES PATENT & TRADEMARK OFFICE

Application of: VON EICHEL-STREIBER, Christoph, et al.

Serial No.: To Be Assigned

Filed: Simultaneously Herewith

For: **TCG METHOD FOR INDUCING TARGETED SOMATIC TRANSGENESIS**

PRELIMINARY AMENDMENT

Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

June 6, 2000

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION :

On page 1, line 7, please insert the following: --This is a 35 U.S.C. § 371 application of International Application No. PCT/EP98/08096, filed December 11, 1998, which claims priority of German Patent Application No. 19754938.1, filed December 11, 1997.

On page 1, line 13, please insert --BACKGROUND OF THE INVENTION--.

"Express Mail" mailing label no. EL 515 149 072 US
Date of Deposit: June 6, 2000
I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above, in an envelope addressed to: "Assistant Commissioner for Patents, Washington, D.C. 20231".
DAVIDSON, DAVIDSON & KAPPEL, LLC
By: Randolph W. McGregor

On page 6, line 29, please insert --SUMMARY OF THE INVENTION--.

On page 7, line 23, please insert the following: --DETAILED DESCRIPTION OF THE INVENTION--.

On page 17, line 18, please insert the following: --DETAILED DESCRIPTION OF THE CERTAIN PREFERRED EMBODIMENTS--.

IN THE CLAIMS :

Please cancel without prejudice claims 1-22, corresponding to the entirety of the claims currently pending in the application. Please add new claims 23-51 as follows:

23. Bacteria useful as a vehicle for gene transport and gene transfer to eukaryotic cells of an organism for inducing a targeted somatic transgenesis in cells, tissues or organs, except the germ-line cells of the organism, the bacteria comprising a foreign DNA integrated into an episomal vector, the transcription and expression of the foreign DNA being under the control of a eukaryotic regulator gene, wherein the bacteria:

a. are vital and viable in the organism;

b. have pathogenic properties selected from the group consisting of:

i. fully pathogenic;

ii. attenuated in one or more of the following ways:

(1) attenuated to prevent the bacteria from inducing apoptosis of the eukaryotic cells,

(2) attenuated to restrict the intracellular motility of the bacteria, and

(3) attenuated so as to permit efficient elimination of the bacteria after the foreign DNA is transferred to the eukaryotic cells; and

iii. naturally not pathogenic bacteria that is provided with additional pathogenicity factors, said factors enabling the bacteria to infect the organism in a controlled manner, to advance into the organs and tissue of the organism, and to transfer the foreign DNA to remote somatic cells;

c. reach the target organ in the organism according to their typical cycle of infection and by their typical route of infection and are able to transmit the foreign DNA into remote somatic cells;

d. have the route of infection that is directed and locally limited either naturally or due to a specific genetic alteration of one or more genes selected from the group consisting of:

i. genes that influence the reproduction of the bacteria in the eukaryotic cells,

ii. genes that reduce the pathogenicity of the bacteria in the organism, and

iii. genes that inhibit the survival of the bacteria in the environment after the bacteria is excreted from the organism; and

e. having the cycle of infection that can be limited in time and terminated by use of an antibiotic.

24. The bacteria of claim 23, in which the foreign DNA is controlled by a promoter and other regulatory sequence, wherein the promoter and other regulatory sequence originate from the previously selected target organ or are optimized from the target organ.

25. The bacteria of claim 23, wherein the bacteria further comprises an additional exogenous suicide gene.

26. The bacteria of claim 23, wherein the bacteria belongs to a genus selected from the group consisting of: Aeromonas, Bartonella, Brucella, Campylobacter, Clostridia, Enterobacteriaceae, Legionella, Listeria, Mycobacterium, Renibacterium, Rhodococcus, and a genus that is genetically or biochemically related to them.

27. The bacteria of claim 23, in which the bacteria contains a dapE gene having a nucleotide sequence set forth in SEQ ID NO. 1 or a gene matching in at least 35% of the nucleotide

positions with the dapE gene, wherein the dapE gene or the matching gene is deleted or inhibited by blocking or mutation.

28. The bacteria of claim 27, wherein the bacteria is of strain Listeria monocytogenes.

29. The bacteria of claim 23, said bacteria containing a cspL gene having a nucleotide sequence set forth in SEQ ID NO 2 or a gene matching in at least 35% of the nucleotide positions with the cspL gene, wherein the cspL gene or the matching gene is deleted or inhibited by blocking or mutation.

30. The bacteria of claim 29, wherein the bacteria belongs to the genus Listeria.

31. A bacterial strain Listeria monocytogenes EGD $HylD_{491A}$, which is deposited at the DSMZ (German collection of Microorganisms and Cell Cultures) under the number of 11881 and is suitable for use according to claim 23.

32. A bacterial strain Listeria monocytogenes EGD Delta actA Delta plcB, which is deposited at the DSMZ (German collection of Microorganisms and Cell Cultures) under the number 11882 and is suitable for use according to claim 23.

33. A bacterial strain Listeria monocytogenes EGD Delta cspL 1, which is deposited at the DSMZ (German collection of Microorganisms and Cell Cultures) under the number 11883 and is suitable for use according to claim 22.

34. The bacteria of claim 23, wherein the bacteria infect udders of cows or other lactating working animals.

35. A method for the production and extraction of proteins, comprising:

a. providing bacteria useful as a vehicle for gene transport and gene transfer to eukaryotic cells of an organism (a TGC procedure) for inducing a targeted somatic transgenesis in these cells, tissue or organs, except the germ-line cells of the organism, said bacteria comprising a foreign DNA integrated in an episomal vector, the transcription and expression of the foreign DNA being under the control of a eukaryotic regulator gene;

b. infecting the eukaryotic somatic cells of the organism with the bacteria to produce transgenic cells, said transgenic cells expressing the foreign DNA to produce a foreign protein encoded by said foreign DNA; and

c. isolating the foreign protein from the cell, tissue or organ, wherein the bacteria:

i. are vital and viable in the organism;

ii. have pathogenic properties selected from the group consisting of

(1) fully pathogenic;

(2) attenuated in one or more of the following ways:

(a) attenuated to prevent the bacteria from inducing apoptosis of the eukaryotic cells,

(b) attenuated to restrict the intracellular motility of the bacteria, and

(c) attenuated so as to permit efficient elimination of the bacteria after the foreign DNA is transferred to the eukaryotic cells; and

(3) naturally not pathogenic bacteria that is provided with additional pathogenicity factors, said factors enabling the bacteria to infect the organism in a controlled manner, to advance into the organs and tissue of the organism, and to transfer the foreign DNA to remote somatic cells;

iii. reach the target organ in the organism according to their typical cycle of infection and by their typical route of infection and are able to transmit the foreign DNA into remote somatic cells;

iv. have the route of infection that is directed and locally limited either naturally or due to a specific genetic alteration of one or more genes selected from the group consisting of

(1) genes that influence the reproduction of the bacteria in the eukaryotic cells,

(2) genes that reduce the pathogenicity of the bacteria in the organism, and

(3) genes that inhibit the survival of the bacteria in the environment after the bacteria is excreted from the organism; and

v. having the cycle of infection that can be limited in time and terminated by use of an antibiotic.

36. The method of claim 35, wherein the method further comprises the step of washing the foreign protein isolated from the cell, tissue or organ.

37. The method of claim 35, wherein the foreign DNA is controlled by a promoter and other regulatory sequence, wherein the promoter and other regulatory sequence originate from the previously selected target organ or are optimized from the target organ.

38. The method of claim 35, wherein the bacteria further comprises an additional exogenous suicide gene.

39. The method of claim 35, wherein the bacteria belongs to a genus selected from the group consisting of: Aeromonas, Bartonella, Brucella, Campylobacter, Clostridia,

Enterobacteriaceae, Legionella, Listeria, Mycobacterium, Renibacterium, Rhodococcus, and a genus that is genetically or biochemically related to them.

40. The method of claim 35, wherein the bacteria contains a dapE gene having a nucleotide sequence set forth in SEQ ID NO. 1 or a gene matching in at least 35% of the nucleotide positions with the dapE gene, wherein the dapE gene or the matching gene is deleted or inhibited by blocking or mutation.

41. The method of claim 35, wherein the bacteria is of strain Listeria monocytogenes.

42. The method of claim 35, wherein the bacteria contains a cspL gene having a nucleotide sequence set forth in SEQ ID NO 2 or a gene matching in at least 35% of the nucleotide positions with the cspL gene, wherein the cspL gene or the matching gene is deleted or inhibited by blocking or mutation.

43. The method of claim 35, wherein the bacteria belongs to the genus Listeria.

44. The method of claim 35, wherein the bacteria is of the strain Listeria monocytogenes EGH H1yD$_{491A}$, which is deposited at the DSMZ (German collection of Microorganisms and Cell Cultures) under the number 11881.

45. The method of claim 35, wherein the bacteria is of the strain Listeria monocytogenes and EGD Delta actA Delta plcB, which is deposited at the DSMZ (German collection of Microorganisms and Cell Cultures) under the number of 11882.

46. The method of claim 35, wherein the bacteria is of the strain Listeria monocytogenes EGD Delta cspL 1, which is deposited at the DSMZ (German collection of Microorganisms and Cell Cultures) under the number of 11883.

47. The method of claim 35, wherein the organism is selected from the group consisting of : (a) a working animal, with the transgenesis being induced in the blood or other tissue of the working animal, (b) a lactating animal, with the transgenesis being induced in the udder of the lactating animal, and (c) poultry, with the transgenesis being induced in eggs of the poultry.

48. A somatic transgenic working animal produced by the method of claim 35.

49. The method of claim 35, in which the somatic transgenic tissue created through infection with the bacterium of claim 1 is reimplanted in an entire organism.

50. The method of claim 35, wherein the foreign protein is selected from the group consisting of hormone, regulation factor, enzyme, enzyme inhibitor and a human monoclonal antibody.

51. The method of claim 47, wherein the foreign protein is useful as a drug, vaccine, or for preparation of diagnostics.

REMARKS

Entry of the amendments set forth herein is respectfully requested. The amendments have been made to more clearly define the Applicants' invention and to better conform the application with the U.S. practices. No new matter has been added by way of these amendments.

Applicants believe the application is now in condition for allowance.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By _____

William C. Gehris
Reg. No. 38,156

Davidson, Davidson & Kappel, LLC
1140 Avenue of the Americas, 15th Floor
New York, New York 10036
(212) 997-1028

SEQUENCE LISTING

<110> von Eichel-Streiber, Christoph
Chakraborty, Trinad

<120> TGC Method For Inducting Targeted Somatic Transgenesis

<130> E 52 P2 Wo

<140> PCT/EP98/08096
<141> 1998-12-11

<160> 4

<170> PatentIn Ver. 2.1

<210> 1
<211> 1260
<212> DNA
<213> Listeria monocytogenes Strain EGD1/2a

<220>
<221> CDS
<222> (241)..(1197)
<223> Sequence of the dapE gene, which is essential for synthesis of diaminopimelic acid.

<400> 1
tgcctttata gagaacggga aaacatagag tggaattcat agaaagaggg cgtgaaatat 60

ggaccaacaa aaaaagattc aaattttaaa ggacttggta aatattgatt cgactaatgg 120

gcatgaagaa caagttgcga actatttgca aaagttgtta gctgaacatg gtattgagtc 180

cgaaaaggta caatacgacc tagacagagc tagcctagta agcgaaattg gttccagtaa 240

```
cga gaa ggt ttg gca ttt tca ggg cat atg gat gta gtt gat gcg ggt   288
Arg Glu Gly Leu Ala Phe Ser Gly His Met Asp Val Val Asp Ala Gly
  1               5                  10                  15

gat gta tct aag tgg aag ttc cca cct ttt gaa gcg aca gag cat gaa   336
Asp Val Ser Lys Trp Lys Phe Pro Pro Phe Glu Ala Thr Glu His Glu
             20                  25                  30

ggg aaa cta tac gga cgc ggc gca acg gat atg aag tca ggt cta gcg   384
Gly Lys Leu Tyr Gly Arg Gly Ala Thr Asp Met Lys Ser Gly Leu Ala
         35                  40                  45

gcg atg gtt att gca atg att gaa ctt cat gaa gaa aaa caa aaa cta   432
Ala Met Val Ile Ala Met Ile Glu Leu His Glu Glu Lys Gln Lys Leu
     50                  55                  60

aac ggc aag atc aga tta tta gca aca gtt ggg gaa gag atc ggt gaa   480
Asn Gly Lys Ile Arg Leu Leu Ala Thr Val Gly Glu Glu Ile Gly Glu
 65                  70                  75                  80

ctt gga gca gaa caa cta aca caa aaa ggt tac gca gat gat tta cat   528
Leu Gly Ala Glu Gln Leu Thr Gln Lys Gly Tyr Ala Asp Asp Leu His
                 85                  90                  95

ggt tta atc atc ggc gaa ccg agt gga cac aga atc gtt tat gcg cat   576
```

Gly Leu Ile Ile Gly Glu Pro Ser Gly His Arg Ile Val Tyr Ala His
100 105 110

aaa ggt tcc att aat tat ccc gtt aaa tcc act ggt aaa aat gcc cat 624
Lys Gly Ser Ile Asn Tyr Pro Val Lys Ser Thr Gly Lys Asn Ala His
115 120 125

agt tcg atg ccg gaa tct ggt gtg aat gcg att gat aac ttg ctg cta 672
Ser Ser Met Pro Glu Ser Gly Val Asn Ala Ile Asp Asn Leu Leu Leu
130 135 140

ttt tat aat gaa gta gaa aaa ttc gtg aaa tca gtt gat gct act aac 720
Phe Tyr Asn Glu Val Glu Lys Phe Val Lys Ser Val Asp Ala Thr Asn
145 150 155 160

gaa ata tta ggc gat ttt att cat aat gtc acc gta att gat ggt gga 768
Glu Ile Leu Gly Asp Phe Ile His Asn Val Thr Val Ile Asp Gly Gly
165 170 175

aat caa gtc aat agt atc cct gaa aaa gca caa ctg caa ggg aat att 816
Asn Gln Val Asn Ser Ile Pro Glu Lys Ala Gln Leu Gln Gly Asn Ile
180 185 190

cgc tcg att cca gaa atg gat aat gaa aca gtg aaa caa gtg cta gtg 864
Arg Ser Ile Pro Glu Met Asp Asn Glu Thr Val Lys Gln Val Leu Val
195 200 205

aag att atc aat aag tta aac aaa cag gaa aat gtg aat ctg gaa tta 912
Lys Ile Ile Asn Lys Leu Asn Lys Gln Glu Asn Val Asn Leu Glu Leu
210 215 220

ata ttt gat tat gat aaa caa cca gta ttt agt gat aaa aat tcg gat 960
Ile Phe Asp Tyr Asp Lys Gln Pro Val Phe Ser Asp Lys Asn Ser Asp
225 230 235 240

tta gtc cac att gct aag agc gta gca agc gac att gtc aaa gaa gaa 1008
Leu Val His Ile Ala Lys Ser Val Ala Ser Asp Ile Val Lys Glu Glu
245 250 255

atc cca tta ctc ggt att tcc gga aca acc gat gca gca gaa ttt acc 1056
Ile Pro Leu Leu Gly Ile Ser Gly Thr Thr Asp Ala Ala Glu Phe Thr
260 265 270

aaa gct aag aaa gag ttc cca gtg att att ttt gga cca gga aac gaa 1104
Lys Ala Lys Lys Glu Phe Pro Val Ile Ile Phe Gly Pro Gly Asn Glu
275 280 285

acc cct cac caa gta aac gaa aat gtt tct ata gga aat tat ttg gag 1152
Thr Pro His Gln Val Asn Glu Asn Val Ser Ile Gly Asn Tyr Leu Glu
290 295 300

atg gta gat gtt tac aaa cgg att gcc acc gag ttt tta tct tga 1197
Met Val Asp Val Tyr Lys Arg Ile Ala Thr Glu Phe Leu Ser
305 310 315

tgaaacttta actttactta tttcccgata taaaataagt aattaataga agtctagtat 1257

ttg 1260

<210> 2

<211> 318
<212> PRT
<213> Listeria monocytogenes Strain EGD1/2a

<400> 2
Arg Glu Gly Leu Ala Phe Ser Gly His Met Asp Val Val Asp Ala Gly
1 5 10 15
Asp Val Ser Lys Trp Lys Phe Pro Pro Phe Glu Ala Thr Glu His Glu
20 25 30
Gly Lys Leu Tyr Gly Arg Gly Ala Thr Asp Met Lys Ser Gly Leu Ala
35 40 45
Ala Met Val Ile Ala Met Ile Glu Leu His Glu Glu Lys Gln Lys Leu
50 55 60
Asn Gly Lys Ile Arg Leu Leu Ala Thr Val Gly Glu Glu Ile Gly Glu
65 70 75 80
Leu Gly Ala Glu Gln Leu Thr Gln Lys Gly Tyr Ala Asp Asp Leu His
85 90 95
Gly Leu Ile Ile Gly Glu Pro Ser Gly His Arg Ile Val Tyr Ala His
100 105 110
Lys Gly Ser Ile Asn Tyr Pro Val Lys Ser Thr Gly Lys Asn Ala His
115 120 125
Ser Ser Met Pro Glu Ser Gly Val Asn Ala Ile Asp Asn Leu Leu Leu
130 135 140
Phe Tyr Asn Glu Val Glu Lys Phe Val Lys Ser Val Asp Ala Thr Asn
145 150 155 160
Glu Ile Leu Gly Asp Phe Ile His Asn Val Thr Val Ile Asp Gly Gly
165 170 175
Asn Gln Val Asn Ser Ile Pro Glu Lys Ala Gln Leu Gln Gly Asn Ile
180 185 190
Arg Ser Ile Pro Glu Met Asp Asn Glu Thr Val Lys Gln Val Leu Val
195 200 205
Lys Ile Ile Asn Lys Leu Asn Lys Gln Glu Asn Val Asn Leu Glu Leu
210 215 220
Ile Phe Asp Tyr Asp Lys Gln Pro Val Phe Ser Asp Lys Asn Ser Asp
225 230 235 240
Leu Val His Ile Ala Lys Ser Val Ala Ser Asp Ile Val Lys Glu Glu
245 250 255
Ile Pro Leu Leu Gly Ile Ser Gly Thr Thr Asp Ala Ala Glu Phe Thr
260 265 270
Lys Ala Lys Lys Glu Phe Pro Val Ile Ile Phe Gly Pro Gly Asn Glu
275 280 285
Thr Pro His Gln Val Asn Glu Asn Val Ser Ile Gly Asn Tyr Leu Glu
290 295 300
Met Val Asp Val Tyr Lys Arg Ile Ala Thr Glu Phe Leu Ser
305 310 315

<210> 3
<211> 1337
<212> DNA
<213> Listeria monocytogenes Strain EGD1/2a

<220>
<221> CDS
<222> (795)..(992)
<223> Sequence of cold shock protein cspL

<400> 3
gaggcaagtg gactaatcat aaagtttttg gcgatgcaac tgcgattttg gcaggagatg 60

ctttactaac gctcgctttt tctattttag ctgaagacga taatttatct tttgagacac 120

gcattgcttt gattaaccaa attagtttta gtagcggtgc agaaggaatg gttggtggtc 180

aacttgcaga cttggaagcg gaaaacaaac aagtgacgct agaagagtta tcatccattc 240

atgcacgaaa aacgggtgaa ttattaattt atgctgtaac ctctgcagca aaaattgcgg 300

aagctgatcc agaacaaacg aaacgcttac gaatttttgc agagaatatt gggattggat 360

ttcaaattag cgacgatatt ttagatgtaa ttggtgatga aacgaaaatg ggtaaaaaga 420

caggggccga cgcttttctg aataaaagta cctatcccgg attactcacg cttgatgggg 480

caaaaagggc attaaatgag catgttacga ttgcaaagtc agcgctttca gggcatgatt 540

tcgatgatga aattctcttg aaacttgctg atttaatcgc acttagagaa aattaatcat 600

aattatctag taatttcaaa atttttttcac atatataatt caaattgatt tgcttttcct 660

aaaataccgt gttatactaa tgtaagatta tttttgtggg tgaaagatac gattgtgaac 720

aactttccat ctcgtgccgt taagcaagaa tagtaaataa ttagtgtgca taacacacga 780

ggaggaacat gaac atg gaa caa ggt aca gta aaa tgg ttt aac gca gaa 830
Met Glu Gln Gly Thr Val Lys Trp Phe Asn Ala Glu
1 5 10

aaa gga ttt ggt ttt atc gaa cgc gaa aac ggt gac gat gta ttc gta 878
Lys Gly Phe Gly Phe Ile Glu Arg Glu Asn Gly Asp Asp Val Phe Val
15 20 25

cat ttc agc gct atc caa ggc gac gga ttc aaa tct tta gac gaa ggt 926
His Phe Ser Ala Ile Gln Gly Asp Gly Phe Lys Ser Leu Asp Glu Gly
30 35 40

caa gca gta act ttc gac gtt gaa gaa ggc caa cgc gga cct caa gca 974
Gln Ala Val Thr Phe Asp Val Glu Glu Gly Gln Arg Gly Pro Gln Ala
45 50 55 60

gct aac gtt caa aaa gcg taattctatt ttttgaataa gaaaaagcaa 1022
Ala Asn Val Gln Lys Ala
65

atcatttcgg tgatttgctt ttttatttgt ctaaaattat tttaccttgt ttggtttaat 1082

ggcgattgtt tgctataata agaacaatta atcgagaaaa aagaccttgc acgcattcat 1142

gcgagtggct ctttggaaag tgagttgttt ttatttggat cttttaaaga taaaggatcc 1202

ttcctttatg aagcgattgg atatacaaga attagaagca cttgcagcgg atattcgcgc 1262

ttttttaatt acttctacat ctaaatcagg tgggcatatt ggtccgaatc ttggtgtggt 1322

agaactaacg attgc 1337

<210> 4
<211> 66
<212> PRT
<213> Listeria monocytogenes Strain EGD1/2a

```
<400> 4
Met Glu Gln Gly Thr Val Lys Trp Phe Asn Ala Glu Lys Gly Phe Gly
 1               5                   10                  15

Phe Ile Glu Arg Glu Asn Gly Asp Asp Val Phe Val His Phe Ser Ala
            20                  25                  30

Ile Gln Gly Asp Gly Phe Lys Ser Leu Asp Glu Gly Gln Ala Val Thr
        35                  40                  45

Phe Asp Val Glu Glu Gly Gln Arg Gly Pro Gln Ala Ala Asn Val Gln
    50                  55                  60

Lys Ala
65
```

09/581005

Dr. Ulrike Rudolph
Patentanwältin
European Patent & Trademark Attorney

D - 69198 Schriesheim
In der Schanz 10

☎ 0049-6203-61348
Fax 0049-6203-64196

Verification Statement

"We confirm that the material on the diskette submitted herewith is identical in substance to the Sequence Listing included in the description of the application entitled "TGC-Method for Inducing Targeted Somatic Transgenesis" based PCT/EP 98/08096.

Schriesheim, Mai 23, 2000

Dr. Ulrike Rudolph

Dr. Ulrike Rudolph

TGC METHOD FOR INDUCTING TARGETED SOMATIC TRANSGENESIS

The object of the invention is a method for inducting targeted somatic transgenesis (TGC = targeted genetic conditioning), which is used for expressing foreign proteins in cells, tissue, organ or an entire host organism, as well as for somatic gene therapy.

It is known that proteins for technical application or for therapeutic purposes can be expressed in sufficient quantity by the transfer of genes in microorganisms or mammalian cells. These procedures are particularly important for proteins occurring naturally in the body, such as hormones, regulatory factors, enzymes, enzyme inhibitors and humanized monoclonal antibodies which are otherwise only available to a limited extent or not available at all. The procedures are also important for producing surface proteins of pathogenic microorganisms or viral envelope proteins so as to safely produce diagnostic tests and for the development of efficacious vaccines. Through protein engineering it is also possible to produce new types of proteins, which through fusion, mutation or deletion of the corresponding DNA sequences, have properties optimized for particular uses, for example immunotoxins.

Genes obtained from human cells are also functional in mouse, rat or sheep cells and there lead to the formation of corresponding gene products. This has already been made use of in the production of therapeutic products, for example in the milk of transgenic farm animals. The hitherto known method has been by the microinjection of corresponding foreign DNA carrying vectors into the nucleus of the fertilized egg cell, in which the DNA is then incorporated into the chromosome with a yield of 1 %. The transgenic fertilized egg cell is then transplanted into hormonally stimulated mother animals. An offspring carrying

the transfected gene in all its body cells is the basis for the creation of a "transgenic herd/flock". Using gene technology it is now possible to alter farm animals in such a targeted way that they produce human proteins in their blood, tissue or milk, which cannot be produced by microorganisms or plants.

However, the use of transgenic animals as protein production factories has the decisive disadvantage that it is necessary to manipulate the germ line of the animal. Due to the considerable expenditure of technology and time required to create and breed transgenic animals and also due to the discussions regarding the ethical consequences of these methods, alternative methods for producing proteins in animal hosts without manipulation of the germ line are necessary and would be very advantageous.

It is known, furthermore, that the milk of mammals such as cows, sheep, goats, horses or pigs can contain a range of disease-causing bacterial agents. Among such agents are Listeria, Mycobacteria, Brucella, Rhodococcus, Salmonella, Shigella, Escherichia, Aeromonads and Yersinia or general bacteria with intracellular lifestyle [1, 2]. These bacteria are usually transmitted to humans or animals through oral ingestion [3], but can also be transmitted by droplet infection. A major source for the infection of humans with Listeria [4], Mycobacteria [5] and Escherichia coli is contaminated milk [6]. Humans ingest the bacteria when consuming unpasteurised milk or milk products. The other bacteria types listed above, such as Salmonella, Shigella, Yersinia, Rhodococcus and Brucella are transmitted to humans in a similar way. However, bacteria may also enter humans through other bacterially infected animal products from cows, goats, sheep, hares, horses, pigs or poultry.

The infection of animals frequently occurs through mucosal surfaces and very frequently through the digestive tract. However, after ingestion of bacteria, for example in the case of Listeria, not all tissues show symptoms of infection. In cows and goats the infection is mainly evident in the udder, spleen and liver. In sheep there may additionally be illness in the central nervous system in the form of meningitis, so not all animals survive the infection. With infection of the udder, the infection chain is closed. With contaminated milk, acquired bacteria can reinfect another animal, for example a suckling calf or a human via the digestive tract.

The following is known at present regarding the process of bacterial infection in humans, here presented using the example of Listeria:

Of the six known Listeria species, only L.monocytogenes and L.ivanovii are pathogenic for humans [7]. Illness in humans results from consuming infected milk or milk products. The course of the illness depends on the state of health of the individual and is generally inapparent. Intrauterine transmission of bacteria to the fetus may occur during pregnancy, resulting in abortion, stillbirth or premature birth. In all cases excellent and problem-free treatment exists using antibiotics such as ampicillin or erythromycin [8; 8a].

The mode of entry into the cell occurs is well defined for L.monocytogenes in humans and animals and for L.ivanovii in sheep. For full pathogenicity of Listeria to occur, a range of pathogenicity factors are necessary. Among them are PrfA (positive regulator of virulence), ActA (actin nucleating protein), PlcA (phosphatidylinositol-specific phopholipase), PlcB (phosphatidylcholine-specific phopholipase), Hly (listeriolysin), Mpl (metalloprotease) [9]. The cell specificity of the pathogen - host cell

interaction is mediated through a range of proteins. Among these are the internalins InlA and InlB, which are involved in the initial contact and the interaction of bacteria and cell surface [10, 11]. Under experimental conditions L.monocytogenes can also infect endothelial cells, epithelial cells, fibroblasts and hepatocytes. In addition, L.monocytogenes can infect cells of the white blood cell count like neutrophilic granulocytes, macrophages and lymphocytes. This is a significant factor in the transmission of bacteria from the site of primary infection to the target organ in the host. Finally, lung tissue can also be infected by Listeria if the bacteria are applied as a droplet infection.

After adhering to the cell surface, L.monocytogenes is taken up by the cell by endocytosis, the bacterium breaks down the endosome membrane under the effect of listeriolysin (Hly) and is thus released into the cell cytosol [14]. Once inside the cell, the bacteria can proliferate. With the production of further proteins, the fully pathogenic bacteria does not stay localized but actively spreads to distal sites . Bacterial spread is effected by using a range of proteins from L.monocytogenes itself and some cellular proteins [15, 16]. ActA is expressed on the cell surface of L.monocytogenes. It binds the cellular protein VASP, which for its part forms the bridge required for the attachment of cellular actin. Actin tails subsequently develop, which carry the bacterium at their tip and thus move it further through the cell. If L.monocytogenes contacts the cell membrane, a membrane protrusion forms, which projects directly into any adjacent cells if they are present. This protrusion is then endocytosed by the adjacent cell so the L.monocytogenes is then inside the new cell within a double membrane. The two membranes are dissolved under the effect of Hly and PlcB [17]. At the end of this process L.monocytogenes has also infected the neighbouring cell and the infection process

begins again. In this way L.monocytogenes enters, for example, secretory cells of the cow udder. Secreted Listeria proteins are detectable in milk, i.e. they are passed on intracellularly from the lactating cell into the milk [18]. Hly (listeriolysin) and IrpA (internalin related protein [19]) are two pathogenicity factors belonging to this group of proteins which are produced, secreted and passed out in milk in large quantities by L.monocytogenes [20].

Knowledge of the infection process has made it possible to alter L.monocytogenes genetically in such a way that it expresses foreign proteins. Examples for the expression of foreign proteins in L.monocytogenes are: alkaline phosphatase from Escherichia coli, nucleoprotein from influenza virus, major capsid protein (L1) from cottontail rabbit papillomavirus (CRPV) and Gag protein from HIV type 1 [20 to 27].

In addition to proteins of prokaryotic origin, this also applies to viral proteins which are not normally produced within eukaryotic cells. These viral proteins and similar foreign proteins of prokaryotic and eukaryotic origin can be produced by L.monocytogenes without a eukaryotic cell being needed. Proteins produced by L.monocytogenes are secreted into the milk.

Infection by bacteria occurs through specific interactions of ligand proteins of the bacteria with receptor proteins of the target cells. In the case of L.monocytogenes, the internalin family plays a significant role; the internalin proteins determine to a large extent the cell specificity of the infection process [28]. Additionally, an ActA dependent cell ingestion has been discussed, which is mediated through receptors of the heparan sulphate family [29]. If L.monocytogenes infects a cell, it does not lead to a full infection cycle in every case. If listeriolysin

in L.monocytogenes is inactivated, the bacteria then remain in the endosome and the infection in the "first cell" does not take place. Bacteria in which the protein ActA is deleted, inactive or no longer available, enter the first infected cell but remain there and can no longer infect the neighbouring cells [30, 31]. If PclB is deleted, the bacteria is no longer able to establish itself in the second cell.

L.monocytogenes is a bacterium which can be treated with a range of antibiotics. Ampicillin and penicillin (always in combination with gentamycin) are particularly suitable. Erythromycin and sulphonamides can also be used as alternatives. Tetracycline, vancomycin or chloramphenicol can also be used in special cases [32]. Similar treatments exist for other bacteria [8a] of the following types: Aeromonads, Bartonella, Brucella, Campylobacter, Enterobacteriaceae, Mycobacterium, Renibacterium, Rhodococcus and other bacteria which are genetically or biochemically related to them.

Given this information, the question arises as to how bacterial infection can be used to induce organotropic protein production.

This problem is solved by a TGC procedure that induces targeted somatic transgenesis, whereby bacteria, carrying a foreign DNA which is integrated into an episomal vector and prepared for subsequent transcription and expression, release their genetic information into an infected single cell when infecting cells, tissue, an organ or the whole host organism and so cause expression of the foreign protein.

This method can be used to obtain a foreign protein but is also advantageous for somatic gene therapy. Here the foreign DNA, introduced into the host organism through

bacterial infection, can cause the production of protein missing in the host organism or, by producing single or double strand nucleic acids, can increase, reduce or hinder the production of a protein in the host organism. This method can be used on all known farm animals and also on humans.

If the infected tissue is the egg of a poultry bird, the foreign protein is produced in the egg and can be isolated following known procedures for the isolation of proteins, for example from hen eggs. If the infected tissue is blood cell tissue, the bacteria can spread via parenteral infection of the cells and through them the foreign DNA can reach the entire infected organism. If the host animals are laboratory animals whose infected organ is an udder, the desired foreign protein is then produced in the milk of the laboratory animal from which the foreign protein can then be isolated.

The TGC procedure is discussed below using the L.monocytogenes bacterium as an example. It can be similarly used, however, for all bacteria which grow intracellularly, in particular bacteria of the following types: Aeromonads, Bartonella, Brucella, Campylobacter, Clostridia, Enterobacteriaceae (in the case of the latter, particularly bacteria of the genus Yersinia, Escherichia, Shigella, Salmonella), Legionella, Mycobacterium, Renibacterium, Rhodococcus and bacteria from genetically or biochemically related types. Other bacteria types which are non-pathogenic and do not have an intracellular lifestyle are also suited to the method according to the invention, as long as they are viable in a eukaryotic host organism.

It is additionally possible to carry out the TGC procedure with naturally apathogenic bacteria which through genetic manipulation are armed with additional factors which enable their entry into cells. Many naturally occuring bacteria

such as Bacillus subtilis, Lactobacilli, Pseudomonads, Staphylococcus incapable of intracellular growth can be additionally equipped with a set of pathogenicity factors, for this purpose. One TGC safety strain armed in this way is, for example, Bacillus subtilis, which is additionally equipped with listeriolysin from L.monocytogenes. An example for the arming of apathogenic bacteria for the TGC safety strain is given in example 1, with the equipping of L.innocua with the hly and/or actA gene from L.monocytogenes. A further example is E.coli K12 armed with the invasin gene (inv) from Yersinia pseudotuberculosis.

The TGC procedure is carried out in the following steps:

a) Cloning of the TGC (foreign) DNA:

The TGC method is initiated with the preparation of L.monocytogenes strain in the laboratory. The cDNA for the foreign protein to be produced is inserted into a suitable vector. The introduction of the cDNA is carried out in a known way so that subsequent transcription and expression in the eukaryotic host is assured. If the protein is secreted from the cell then the vectors must contain suitable host cell specific secretory signal sequences. The vector can be a eukaryotic vector, for example pCMV from the company Clontech or pCMD from the company Invitrogen, both of which are commercially available. As important criteria for chosen vectors, these have eukaryotic promoters, donors and acceptor sites for RNA splicing (optional property), as well as a polyadenylating site, for example from SV40. The production of genetic constructs (hereafter referred to as TGC DNA below) in E.coli, or any other suitable host strain according to the method, can be carried out for the propagation of the DNA. The TGC DNA must simply be able to be introduced into the selected bacteria for the primary cloning and then later transferred into the selected bacterial TGC safety strain. The transfer

into L.monocytogenes can be carried out using the various well-known methods of gene transfer of isolated DNA (transformation, electroporation etc.) or can be undertaken using the processes of conjugation and transduction either directly or indirectly from bacterium to bacterium.

b) TGC safety strains as recipients of TGC DNA:

Special L.monocytogenes host strains are used as recipients of the TGC DNA, - or other TGC hosts, which like L.monocytogenes are intracellularly active bacteria (e.g. Yersinia) or bacteria which enter the endosome (e.g. Salmonella) or are "armed" with additional bacterial factors, or alternatively, otherwise non-pathogenic bacteria (e.g. Escherichia coli or L. innoca). In all these cases the following properties, singly or in combination, must be met:

(A.1) they are suitable as recipients of foreign DNA (genetic manipulability);

(B.1) they carry mutations which affect genes, without which survival of the bacteria in the environment (outside the host) is not possible, for example, at low ambient temperatures (safety related property);

(B.2) they are attenuated host strains, for which a part of their virulence factors are deleted or inactivated so that they no longer possess the full pathogenicity of the wild-type strains (attenuation);

(C.1) they are "genetically disabled" and can only be cultivated on defined artificial media due to targeted metabolic defects introduced by the experimenter. As a result of these defects they

are incapable of growth in a cell and in particular in the animal host and thus cannot proliferate and undergo "endogenous suicide";

(C.2) they induce their uptake in endosomes and are dissoluted in these cell compartments (infection via endosomes);

(C.3) they are ingested by professional phagocytes but can dissolve these cell compartments (i.e. egress) (infection through phagolysosomes);

(C.4) the bacteria carry suicide genes which are only conditionally activated after invading the host cell, so the bacteria kill themselves ("exogenous suicide");

(D.1) they can be eliminated by antibiotic treatment of the intended animal host (killing off through antibiosis).

Point A.1 is a general property of bacteria, without which none of the genetic manipulation mentioned would be possible.

Points B.1 and B.2 summarize alterations which make the use of the bacteria safer. Bacteria with these alterations cannot proliferate if released to the outside world, are attenuated (B.1), or show reduced pathogenic potential (B.2). The alteration of bacteria according to point B.1 has an influence on the release of foreign DNA into the cell (see points C.2 and C.3).

Points C.1 - C.4 refer to genetic alterations of bacteria which decisively determine the release of the foreign DNA into the animal cell. In points C.3 - C.4 are indicated ways of infection which for bacteria, further summarized

below in the examples, were identified as a means for the transmission of foreign DNA into the cytosol of animal cells.

Antibiotic treatment carried out in point (D.1) permits the targeted destruction of bacteria. As a result of this, foreign DNA is released from the bacteria and therapy with antibiotics is also a safety relevant feature.

The alterations and interventions of C.1 - C.4 and also B.2 and D.1 enable the release of recombinant DNA into the cell.

Strains with these properties (singly or in combination) are called TGC safety strains.

c) Optimization of the TGC hostss to the target organ of the TGC procedure:

The TGC DNA which codes for the foreign protein to be produced is transferred into the TGC safety strain by transformation, conjugation or transduction. The strains thus obtained are subsequently referred to as TGC hosts. The host supplies (feeds) the TGC host with DNA and thereby induces somatic transgenesis. In order for the desired foreign protein to be optimally expressed during the TGC process, the gene should be preferably controlled by promoters and other regulatory sequences that either originate from the preselected target organ of the TGC process or are optimized for the target organ, as for example with udder specific promoters and secretion signals.

d) Infection of the host organism with the TGC host:

The propagation of the TGC host by cultivating in vitro in a culture medium is used to prepare it for carrying out the

TGC process in the selected host organism. The TGC host strain can alternatively also be propagated in the host organism (human or animal, denoted as TGC host), by in vivo cultivation. In preparation for infection, the TGC host strain is suspended in a non-bactericidal solution adapted for the TGC host, in a buffer or in another physiological liquid. The liquid is administered to the TGC host, for example to the lactating mammal if the udder is to be made somatically transgenic. This can be carried out perorally by drinking the liquid or by supplying it via a stomach tube, the anus or another body orifice. The administration of the TGC host strain by injection is an alternative possibility and can be done intravenously, intramuscularly directly into the target organ or, preferably, intraperitoneally. A further alternative is infecting by producing an aerosol and then inhaling the droplets.

The TGC host (human or farm animal: cow, horse, goat, sheep, pig, hare, poultry etc.) can be infected several times with the same or heterologous transgenes. By repeated infection with different DNA which, for example, code for several enzymes of a biosynthetic pathway, whole enzyme cascades can be established in the TGC host. The biochemical expression of multigenic proteins can thus also be achieved.

e) Organ and cell specificity of infection:

The subsequent path of the TGC host strain in the organism is determined by the natural route of infection. The TGC host strain reaches the target organ using the route typical for the respective bacterium. If the TGC host strain carries genetically unaltered internalin, as in the case of L.monocytogenes, then the udder will be among the target organs. Genetically altered internalins permit the infection of other organ systems. Depending on its infection cycle, the TGC host strain penetrates into the

cells and appears in the cytoplasm. As it is genetically defective, the TGC host strain cannot proliferate there and it undergoes "endogenous suicide" (see C.1 under b) above). With cell infection the TGC host strain has introduced the host-foreign TGC DNA into the cell. The transfer of foreign DNA into the cell can, however, also be brought about by "exogenous suicide" (see C.4 under point b) above) or by elimination the bacteria through specific antibiotic treatment (see C.3 under point b) above). In these three cases the bacteria cells carrying the foreign DNA die within the animal cells and thereby release the foreign DNA into the cytoplasm. Finally, the transfer of the foreign DNA into animal cells can also be achieved by targeted infection of cells with absence of lysis of the endosomes. The foreign DNA of the animal cells is thus available within the endosomes by lysis of the bacteria.

In each of the cases mentioned, the DNA transferred into the cells is now available as a template for the production of the desired foreign protein. The nucleic acid can also have a direct therapeutic effect however, for example by the generation of anti-sense RNA. The cells, tissue or organ manipulated in this way became somatically transgenic in the course of the infection.

f) L.monocytogenes induced protein production in the milk of mammals

After carrying out the TGC procedure - for example with TGC host strain such as L.monocytogenes or other intracellularly active bacteria (e.g. Yersinia) or bacteria which penetrate the endosome (e.g. Salmonella) or are "armed" with additional bacterial factors, or otherwise non-pathogenic bacteria (e.g. Escherichia coli or L.innocua) - the protein is created in the lactating cell and passed out into the milk with the other products of the cell. If several animals are made somatically transgenic

with different foreign DNA in a TGC process, then the different proteins can be produced, separated from each other, by collecting the milk of each single TGC host (milking).

Due to the properties of the TGC host strain, no L.monocytogenes (TGC host strain, i.e. host bacterium) appear in the milk. Should this be the case however, then the bacteria can be eliminated using the methods familiar to an expert in the field, for example by treating with antibiotics. Animals (or also humans) are free of any viable, genetically engineered organisms after carrying out targeted genetic conditioning (TGC) and do not therefore have to submit to any further safety checks. The TGC host transmits the genetic information introduced into it by the TGC process to the offspring cells in the context of usual cell division. The information is not transmitted to the descendants of the TGC host however, as the TGC DNA is not present in the germ line of the TGC host. The avoidance (i.e. omission) of genetic manipulation of the germ line of the whole organism and targeted protein production in a predetermined organ or tissue of the animal host (animal and human) constitutes the innovative and new aspect of the method according to the invention.

g) Infections of tissue by L.monocytogenes

Blood is a tissue whose genetic alteration using the TGC method according to the invention will be described as an example. Blood cells are particularly suited for the TGC method. It is possible to infect blood cells outside the body. The desired somatic transgenesis of the cells can similarly be monitored outside the host. In the case of attenuated auxotrophic bacteria - diaminopimelic acid is here used as an example for auxotrophy - the substances necessary for the growth of the cells can be added to the medium and thus control the life span of the bacteria

according to the experimental objective. It is possible to check whether the intracellular bacteria are still alive by subsequent lysis of the animal cells.

The transfected cells, containing a well defined quantity of live bacteria, are finally used for reimplanting in the recipient organism. In particular cases there can be such a large number of bacteria that additional organs in the organism are infected. In other cases transgenesis is specifically restricted to the blood tissue by the in vitro elimination of live bacteria before reimplantation in the TGC host.

Reimplantation and the connected dissemination of transgenic cells with or without live bacteria permits somatic gene therapy of cells in the host, which in this case may also be a human host.

The TGC method also enables extracorporal proteins to be produced. For this purpose TGC host strains are injected into the eggs of poultry birds. Suitable techniques for this are state of the art in the production of vaccines by viral agents. During the incubation period the cells in the egg are infected in a somatic transgenic process and then produce the foreign protein. The foreign protein can be purified from the egg using state of the art techniques. With this type of TGC process the TGC host strain remains controllable in all stages of use under laboratory conditions. The quantity of protein to be produced depends only on the injection of a correspondingly large number of eggs.

h) Use of the TGC method for somatic gene therapy

There is not yet an established form of somatic gene therapy. At present the nucleic acid used for transfection

is protected from the influence of the outside world within viruses or packed in liposomes.

Viruses have the disadvantage that they only have a limited size uptakecapacity and that the development of their full cytopathic effect at high infection doses must be taken into account [32a]. They induce immune reactions and so can be attacked and destroyed themselves. Some viruses are inactivated by serum and are then unusable for gene therapy. Here particularly, mention should be made of the multiple dosage of viruses for gene therapy, in the course of which the immune response of the host is stimulated. The creation of a specific defence aimed against viruses has proved to be a significant problem in the use of viruses in the context of gene therapy.

When using liposomes, the toxic effect of lipids in provoking inflammatory reactions must be considered.

In the case of in vivo therapy there are still considerable obstacles to using the gene transfer systems used so far. For this form of therapy it is necessary to have [32b]:

(i) Resistance of the vector against breakdown after in vivo administration in the body,

(ii) Tissue specificity, i.e. targeted control of the tissue (organ) being subjected to therapy and

(iii) Safety, by which is meant harmlessness to organs not being treated [32b].

The bacteria described in this patent application, which function as a vehicle for gene delivery are ideally suited for gene transfer. The bacteria are optimally adapted to their corresponding host and can survive in it for a sufficient length of time without external intervention,

such as antibiotic therapy. They induce specific diseases following a defined route of infection and in so doing partly display marked organotropy. They can take up considerable quantities of foreign DNA (e.g. naturally occurring plasmids have sizes of several hundred kilobases), so not only cDNA's but even larger regions of a chromosome can be transferred. Finally, they can be used safely, particularly if "disabled" bacteria are used, as described above. The genetic defects of the TGC host strain, in combination with their antibiotic sensitivity, assure efficient elimination of the bacteria after they have completed their task of DNA transfer into eukaryotic cells.

Example:

Examples for somatic gene therapy are listed below:

- Therapy for cystic fibrosis (CF): the bacterium must here be administered by inhalation to the patient undergoing therapy. The bacterium used should preferably be a bacterium which is transmitted through droplet infection. The bacterium contains the CFTR gene, which can cure the crucial defect occurring in CF. The bacterium penetrates into the airway lumen-facing columnar cells and transfects them with the CFTR DNA integrated into the TGC vector. The cells become somatically transgenic, the defect is cured.

- β-thalassaemia can be treated by somatic gene therapy with human β-globulin gene. Ex vivo cells that originate from the haemopoetic system are infected with a TGC safety strain, which transfers the β-globulin gene into the original cell. The infecting bacterium is eliminated by treatment of the cells in the cell culture and the transgenic cell is prepared for transfer back into the

human. This transfer takes place through intravenous administration.

- In therapy of Hurler syndrome, naive CD34 positive cells of the bone marrow are transfected with α-L-iduronidase gene. The way gene therapy is carried out and the transfer of the cells back into the patient are as described in the preceding example.

- In gene therapy of Fanconi anaemia, the gene of the Fanconi anaemia complementation group C (FACC) is used for somatic gene therapy. The target cells of the infection with TGC host strain are again CD34 positive cells of the bone marrow.

i) Proof of the success of TGC method

DNA transfer is already evident in mice within the first 24 hours, i.e. long before a specific immune response against the bacterium could arise. This was demonstrated by the production of β-galactosidase or the green fluorescent protein (EGFP) in cell cultures within 24 hours. The "mitogenetic effect of bacteria", which additionally occurs in the context of infection, favours the establishment of DNA in the TGC cell and is therefore desired and advantageous for the success of the TGC process.

In summary, it can be established that the use of bacteria for somatic gene therapy is safer than gene therapy using viral systems. Bacterial infection can both be directed and restricted locally. Growth and hence florid infection by the bacteria can be prevented by removing particular bacterial factors. Additionally the growth of bacteria in eukaryotic cells can be directly influenced and generally prevented. Finally, the termination of bacterial infection is possible at any time through the use of antibiotics,

i.e. the place, time and effectiveness of the infection can be controlled.

The invention is described in detail below, using L.monocytogenes as an example:

Example 1: Production of TGC safety strains

The L.monocytogenes safety strains are produced by targeted genetic alterations of primary pathogenic L.monocytogenes. In so doing, several levels of safety are established together. Recurrence of vitality or pathogenicity caused by reversion of the mutations is prevented. The mutations affect genes which (1) influence the survival of bacteria in the cell, (2) which diminish the pathogenicity of the bacteria in the TGC host and (3) which prevent survival of the bacteria in the environment, should any escape.

a) First level of safety - <u>safety relevant property:</u> survival in the environment (see point B.1 under b) above)

TGC host strain s can be applied to the TGC host either by injection or by peroral administration. With peroral administration there may be a surplus of bacteria, resulting in secretion of bacteria, which are not ingested by the organism. In order that these eliminated bacteria have no opportunity of surviving in the environment, the TGC safety strain can contain additional mutations which prevent the growth of the bacteria in the environment.

As an example for this, the switching off of the cspL gene (cold shock protein of Listeria) is indicated. This has the consequence that the bacteria can no longer grow at temperatures under 20 °C. Growth and ability to infect at 37 °C are not adversely affected, but are additionally modulated by simultaneous mutations according to a) and b).

The cspL gene, which is deleted in the safety strains used in this invention, is shown in the sequence protocol under SEQ. ID No. 2. A corresponding cspL deleted strain has been deposited at the DSM under No. 11883 with the description L.monocytogenes EGD delta cspL1.

The TGC safety strains of the invention can only be cultivated on special growth substrates. The growth temperature must be above 37 °C, growth is not possible below 20 °C. The bacteria possess limited pathogenicity and are only capable of penetrating restricted, tightly defined areas of the TGC host. In this way safety of the system for humans and the environment is assured. The TGC host strains are no longer able to grow outside the artificial media, here specifically, the host cell. This restricted intracellular viability is at the same time a prerequisite for the release of TGC DNA in the host cell and hence for the induction of somatic transgenesis using the TGC method.

b) Second level of safety - attenuation: reduced pathogenicity (see point B.2 under b) above)

The second level, of attenuation of the TGC safety strains includes mutations in the pathogenicity factors. Through targeted mutations in defined factors, pathogenicity in the bacteria is reduced, induced apoptosis of infected host cells is prevented and the immune reaction is at the same time directed in the desired direction. The mutations restrict the intracellular motility of the bacteria and hence their spread to secondary cells. The infection is thus limited to the chosen target cells, with retention of treatment using antibiotics.

For safety considerations it is desirable to restrict or even prevent the intracellular spread of TGC nurse after infection. Accurate knowledge of the intracellular lifestyle and the motility of the above mentioned bacteria

makes it possible to produce defined, stable mutants with reduced ability to infect the TGC host.

With L.monocytogenes, the mutations attenuated in this way affect, for example, the hly gene with consequent blocking of infection in the first cell. An example for the switching off of this pathogenicity factor, the strain L.monocytogenes EGD Hly_{D491A} has been deposited and has received the number DSM 11881.

Another example for the reduction of pathogenicity of L.monocytogenes are mutations in actA gene or the deletion of regions which are necessary for the interaction between actA and the host cell protein VASP, with the consequent blocking of intracellular motility. Finally, there are mutations of plcB gene, in which bacteria are disabled for spread into a second cell. The deposited strain L.monocytogenes EGD delta actA delta plcB is an example of a double mutation in which both the actA gene and the plcB gene are removed . It has deposit number DSM 11882.

It is additionally possible to exchange the wild-type listeriolysin gene in L.monocytogenes for a mutated allele. The properties of the listeriolysin are then restricted, both for inducting apoptosis in various host cells and also for generating a strong T cell mediated immune response.

c) Survival in the cell: - endogenous suicide: third level of safety (see point C.1 under b) above)

In general one of the features of attenuated bacteria for the TGC process is their having defined deletions in the genes which are essential for the biosynthesis of integral bacterial components. The selected auxotrophic bacteria are suitable as TGC host strains, since, being attenuated bacteria, they can transport foreign DNA into the cell. However, as the bacteria in the cells lack essential

"growth factors", they spontaneously lyse and thereby release TGC DNA in the cell.

L.monocytogenes are used as TGC safety strains. They are genetically altered in such a way that although they infect the cell, they can no longer multiply in the cell. This is achieved by, for example, inactivating the dapE gene in L.monocytogenes. Listeria are gram positive bacteria which, just like gram negative bacteria, require meso-diaminopimelic acid derivative (DAP) for cross-linking of the cell wall. Biosynthesis of diaminopimelic acid is therefore essential for the creation of the bacterial cell wall. DAP auxotrophic bacteria succumb to spontaneous lysis if this amino acid is no longer supplied in the culture medium. The enzymes which are involved in DAP synthesis in bacteria are not present in mammalian cells. In TGC safety bacterial strains, these enzymes are also deleted or inactivated by insertions or other means. The dapE of L.monocytogenes, which was inactivated in the safety strains used according to the invention, is shown in the sequence protocol as SEQ. ID No. 1. For the genetic manipulation of the dapE gene in L.monocytogenes, its sequence had to be determined, as corresponding genes, e.g. from E.coli, has only about 30 % homology to the sequence of SEQ ID No. 1 protocol.

The bacteria deleted for this or other genes of the DAP biosynthesis pathway, so called DAP mutants, cannot grow either within or outside the host. In order to grow they require the addition of a large quantity of DAP (1 mM) to the growth medium. If DAP is missing, the bacterium cannot survive either in the TGC host or outside the TGC host. These DAP mutants hence provide safety, both against a bacterial infection of the TGC host and safety against an infection of other organisms in case of release of a strain of this type into the environment.

A manipulation of the genome of Salmonella (creation of an auxotrophic mutant) shows that the deletion (or blocking or mutagenesis) of the aroA gene, which is essential for the synthesis of aromatic amino acids, has the same effect. From the Salmonella vaccine strain (available from the American collection of bacterial strains under the number ATCC14028), a mutant can be produced by genetic manipulation using techniques well-known to experts, and with knowledge of the aroA gene sequence (Genebank accession number M10947). This mutant can function as a TGC safety strain in a similar way to the recombinant bacteria here described for Listeria. Release of foreign DNA occurs, as for the above described L.monocytogenes delta dapE strain, through the bacteria dying off after their uptake into the cell. Unlike L.monocytogenes, Salmonella cannot enter the cell cytoplasm. Release of the foreign DNA in this case occurs from the endosomes into the cell cytosol.

Other attenuated mutations of L.monocytogenes are also known, in which biosynthesis of nucleic acids, amino acids, sugars or other essential cell wall ingredients, is blocked [33 to 35]. The same can also be achieved through mutations in regulatory genes which are essential for the intracellular lifestyle of the bacteria. An example of a gene of this type is phoP of Salmonella typhimurium [36].

The examples described here for L.monocytogenes can be applied to other intracellular live bacteria or bacteria which are first made into intracellular activators by being armed with pathogenicity factors. This is especially the case for bacteria of the types Aeromonads, Bartonella, Brucella, Campylobacter, Clostridia, Enterobacteriaceae (particularly E.coli, Salmonella, Shigella, Yersinia), Mycobacterium, Renibacterium and Rhodococcus. A TGC safety strain accordingly armed, for example, Bacillus subtilis, which is additionally equipped with listeriolysin from L.monocytogenes.

An important prerequisite for transfer of DNA itself into cells distal in the body is the protection of the DNA on its way to the target cell or target tissue or target organ. The ability of intracellular live bacteria such as L.monocytogenes to spread intracellularly is an ideal property for transporting genes into isolated cells, deeper tissue and organs. The vehicle, the TGC host strain, dies after successful transfer of TGC DNA into the target cell, as a consequence of attenuation (B.1), induction of auxotrophy (B.2), endogenous suicide (C.1), infection by endosomes (C.2), infection by phagolysosomes (C.3), exogenous suicide (C.4) or antibiotic therapy (D.1).

Example 2: Release of foreign DNA in animal cells (tissue or organ)

a) Infection via endosomes: Transfer of the expression plasmid without release of the bacteria from the endosome vesicle (see point C.2 under b) above)

Tests were carried out to see if bacteria are able to transfer their plasmid DNA into the cytoplasm of infected host cells, without it being necessary for them to first escape from the endosome vesicle. The ability of L.monocytogenes Δhly mutants, which can no longer leave the endosome, to function as a transfer bacterium for DNA transfer was investigated. EGFP was chosen as the foreign DNA to be transferred. It is a fluorescent protein which was cloned under the control of a CMV promoter. As a measure for successful transfer of foreign DNA - i.e. as a measure for transfection of the eukaryotic cells - 10,000 cells were examined in a FACS scanner for the occurrence of EGFP dependent fluorescence, after infection with the corresponding L.monocytogenes strains. The number is expressed in Table 1 as a percentage of the total number of measured eukaryotic cells. L.monocytogenes wild-type strain

EGD served as a positive control during the experiments. An isogenic non-invasive ΔInlAB strain was also tested. The evidence obtained with these bacteria have general validity and are transferable to other bacteria.

The results are summarized in Table 1 and show that Δhly mutant is just as efficient as the wild-type L.monocytogenes strain with regard to DNA transfer from the bacterium into the eukaryotic cell. The L.monocytogenes ΔInlAB strain is not suitable (PtK2) or is significantly worse (Hep-2) as a vehicle for DNA transfer into the cells here indicated. The experiments also show that the active uptake of bacteria by eukaryotic cells (in this case non-professional phagocytes) is a precondition for transfection of cells. The attachment of bacteria is effected by the interaction between bacterial internalins (InlA and/ or InlB) and the receptors of the animal cells. The experiments of the following example demonstrate that internalin is not necessary for the uptake of bacteria in professional phagocytes.

Cell line	**Origin**	**L.monocytogenes strain**	**Transfected cells in %**
PtK2	Kangaroo rat kidney	Wild-type EGHD	1.71
		Δhly	1.78
		ΔinlAB	0
Hep-2	Human larynx carcinoma	Wild-type EGHD	4.58
		Δhly	4.31
		ΔinlAB	0.24

b) Infection through phagolysosomes: Arming of non-pathogenic strains as TGC safety strain; (see point C.3 under b) above)

The example shown below for L.innocua is representative and can be extended to other non-pathogenic bacteria (e.g. Escherichia coli). The steps leading to the genetic manipulation of such bacteria correspond to those here indicated for L.innocua.

A non-pathogenic L.innocua strain (Serovar 6a) was "armed" with the pathogenicity factors listeriolysin and ActA from listeria monocytogenes. In order to be able to regulate this gene, the positive-regulatory factor (PrfA) was cloned as third gene into genetically engineered L.innocua strain. The presence of PrfA causes expression of the virulence gene to be growth temperature dependent. As this recombinant L.innocua strain possesses no internalin, i.e. is not itself invasive, it cannot penetrate into the above mentioned cells (Ptk2, Hep-2). If the experimenter wishes to be able to also infect these cells, then the bacteria must additionally be equipped with the internalins InlA and/ or InlB. The experiments of the present example show that there is no need of these bacterial products (internalins) for the ingestion of L.innocua (hly+; actA+) strain by professional phagocytes. After their phagocytosis, the L.innocua strain (hly+; actA+) uses the protein listeriolysin for the lysis of the phagolysosomes of the professional phagocytes. It can be seen from the electron micrographs that the genetically manipulated L.innocua (hly+; actA+) strain appears in the cytoplasm of the professional phagocytes. The wild-type strain L.innocua Serovar 6a, on the other hand, is killed off in the phagolysosome and does not appear in the cell cytoplasm. Expression of the ActA-protein enables the L.innocua (hly+; actA+) strain to have an actin cytoskeletal-dependent intracellular movement, which appears similar to the movement of the L.monocytogenes strains in the EM images. Due to the failure of further genes, such as e.g. the plcB gene, the L.innocua (hly+; actA+) strain mentioned here

cannot spread to neighbouring cells. This specific alteration in infectivity has already been described for recombinant L.monocytogenes ΔplcB strains.

The targeted selection of genes, here hly and actA, and their transformation into non-pathogenic bacteria, transfers the selected L.monocytogenes properties to non-pathogenic bacteria. The escape of the bacteria from the "deadly" phagolysosome is a precondition for the transfer of foreign DNA into infected cells. The DNA which is to be transferred for the reprogramming of animal cells, is thereby integrated into host strains, as described above for attenuated L.monocytogenes bacteria - which according to the invention can be used as such. The release of the genetic information according to the invention occurs through (i) creation of auxogenous mutants (deletion of endogenous, life-essential genes), (ii) through introduction of "suicide genes", (iii) through induced ingestion into endosomes and killing off there or (iv) through antibiotic therapy which is temporally defined and directed to killing bacteria in a target organ or tissue.

The experiments of this example are representative of how naturally occuring non-pathogenic bacteria can be consecutively "armed". By equipping them with defined bacterial factors (here genetic i.e. properties of naturally invasive bacteria), bacteria which are otherwise primarily unsuited for the TGC method can be manipulated and directed in such a way by the experimenter so that they can be used for controlled infection and transfer of DNA into animal cells (or tissue, organ, whole animal, human).

c) Release through exogenous suicide: Cloning of suicide genes: (see point C.4 under (b) above)

Suicide genes, which are activated after penetrating into the host cell and lead to death of the bacteria, can be

supplied to the bacteria in the form of lysis genes from bacteriophages, for example with the S-gene of the lamda or analogous bacteriophages [37], or with killer genes from plasmids [38]. These genes are controlled by an intracellular inducable promoter (for example pagC-promoter from Salmonella [38]).

d) Release through antibiotic therapy: Targeted release of foreign DNA in the lung after droplet inhalation of Listeria monocytogenes (see point D.1 under (b) above).

Infection with bacteria took place according to the method "Body plethysmography in spontaneously breathing mice" by R. Vijayaraghavan [Arch. Toxicol. 67: 478-490 (1993)]. In the experiment mice were exposed singly for half an hour in an inhalation chamber to an aerosol of one millilitre of bacterial suspension, which contained a total of 5000 bacteria. This quantity of bacteria corresponds to the LD50 dose of intraperitoneally administered bacteria. In order to be able to follow the course of the infection in real time, the bacteria were once more transformed with a EGFP-gene construct. Using fluorescence analysis of the EGFP-protein formed in the tissue, the route of infection of the bacteria in the animal model was followed. Within half an hour the bacteria penetrate into the columnar and endothelial cells of the air passage. At this point no bacteria are to be found in other tissue or organs of the infected animal, such as e.g. spleen, liver, brain. The infection remains exclusively restricted to the lung for up to 18 hours. Only after 24 hours are other organs also affected.

The experiment shows that the spread of bacteria after droplet infection can be restricted to the primary organ if there is an intervention into their viability. Two ways of achieving this are by using attenuated mutants (e.g. ActA deleted in the "spreading gene") and/ or by destroying the

bacteria through initiating antibiotic therapy at a time determined by the experimenter, i.e. in an organ determined by the experimenter.

Example 3: Description of the TGC vectors

TGC vectors are episomal DNA, for example plasmids with low ingestion capability for foreign DNA (pMB derivatives which are sufficient for single genes), or plasmids with greater DNA ingestion capability (such as in Pl- or F-plasmids), in order to create somatic transgenesis for complex biosynthetic pathways.

In all cases, the plasmids involved are replicated in the bacteria hosts which are used for genetic alteration and cultivation for the TGC process. E.coli, or other bacteria commonly used in recombinant DNA techniques, are suited as examples of an intermediate host in which genetic building blocks can be constructed. L.monocytogenes or other above-mentioned bacteria functioning as TGC host strainss are suitable as a TGC safety strain. In order to fulfil this condition, the plasmids contain the host-specific plasmid replicon sequences. During the process of generating recombinant DNA, the transformed host cells must be distinguished from "naked" host cells. Generally, common antibiotic resistance genes can be used as selection principles for this.

Example 4: Transformation of L.monocytogenes safety strains to TGC host strains

The transformation of L.monocytogenes is carried out according to a modified protocol of Park and Stewart [40].

Accordingly, bacteria are applied up to an optical density of OD_{600} = 0.2. Ampicillin (10 µg/ml) and 1 mM glycine are added to the culture medium. Further proliferation occurs

up to an OD_{600} of 0.8 to 1.0. The cells are harvested by centrifugation and resuspended in 1/250 vol. cold electroporation buffer (1 mM Hepes, pH 7.10, 0.5 M sucrose). The bacteria are washed up to four times prior to electroporation.

For electroporation, 50 µl of the prepared cells are added to an electroporation cuvette, electroporation is carried out using 1 µg DNA at 10 kV/cm, 400 ohms, 25 µF.

After electroporation the cells are immediately cooled on ice, suspended in 10x BHI medium and incubated for 2 hours at 37 °C with careful agitation. After this the cells are plated and incubated at the desired temperature. The efficiency of transformation with this method is 10^4 to 10^5 transformers per µg plasmid DNA used.

Example 5: Description of the cultivation of TGC host strains for use in the TGC method

Listeria were preferably cultivated in the brain-heart infusion broth, for example BHI of the Difco company. Alternatively, and for special applications (radioactive labelling of listerial proteins), the bacteria can be cultivated in tryptic soy broth (TSB) or in Listeria minimal medium (LMM) [36]. The bacteria are centrifuged off and washed several times in a suitable transfer medium, for example, a bicarbonate containing buffer.

Bacteria prepared in this way can be kept for at least 6 months at -80 °C with the addition of 15 % glycerine solution, before they are used in the TGC procedure.

Example 6: TGC method - use of TGC host strains as nutrient

As an introduction to the TGC process, the animals are not allowed to drink for a few hours. The (TGC host strain : TGC-DNA in the desired strain) are infused in a bicarbonate containing buffer of suitable concentration and administered to the animals orally, by inhalation or by injection (parenteral, intramuscular, intraperitoneal or directly into the target organ). The type of application is determined by the physiological route of infection of the corresponding TGC hot strain. The selection of the bacterium which is used as TGC safety strain depends on the target organ and is established according to the path of infection and according to the organotropy of the relevant bacterium. The dosage of bacteria is chosen so as to achieve the desired organotropic transfection of the TGC host strain. The quantity and type of bacterial application thus depends on the particular bacterium, but also depends on the host and target organ (see also example 2).

Example 7: Implementation of somatic gene therapy

Examples for somatic gene therapy are listed below:

- Therapy for cystic fibrosis (CF): the bacterium must be administered by inhalation to the patient undergoing therapy. The host used should preferably be a bacterium which is transmitted through droplet infection. The bacterium contains the CFTR gene, which can cure the crucial defect occurring in CF. The bacterium penetrates into the airway lumen-facing columnar cells and transfects them with the CFTR DNA integrated into the TGC vector. The cells become somatically transgenic, the defect is cured.

- β-thalassaemia can be treated by somatic gene therapy with human β-globulin gene. Ex vivo haematopoetic stem cells are infected with a TGC safety strain, which transfers the β-globulin gene into the original cell. The

infecting bacterium is eliminated by treatment of the bacteria in the cell culture and the transgenic cell is prepared for transfer back into the human. This transfer takes place through intravenous administration.

- In therapy of Hurler syndrome, primitive CD34 positive cells of the bone marrow are transfected with α-L-iduronidase gene. The way gene therapy is carried out and the transfer of the cells back into the patient are as described in the preceding example.

- In gene therapy of Fanconi anaemia, the gene of the Fanconi anaemia complementation group C (FACC) is used for somatic gene therapy. The target cells of the infection with TGC host strain are again CD34 positive cells of the bone marrow.

Example 8: Monitoring the success of induced somatic transgenesis

After the TGC DNA has been transferred into the TGC host, the success of the TGC process has to be monitored. Immunological methods for detecting gene products (proteins) are suited for this, such as immunoassays (e.g. ELISA), immunoblot or other well-known methods which involve an antigen-antibody reaction. T-cell responses can be measured in special assays and are always used when the antigen is a substance that is recognized via MHC-class 1 mediated immune responses.

If the protein produced is an enzyme, then its biological activity can be determined in the form of an enzyme activity test. If the protein additionally possesses biological activity, then the efficiency of the protein produced can be measured with biological assays.

For proteins that induce passive or active immunisation of the TGC host, protection against the activating agent can be tested; for example, the prevention of colonisation, infection (or apparent disease) in the experimental animal after exposure to the pathogenic organism (bacterium or virus).

Example 9: Harvesting the protein

The protein to be produced can be obtained using state of the art techniques that are common knowledge to persons involved in animal husbandry:

- if the TGC host is a cow or other lactating farm animal and the udder is the infected organ, then the well-known techniques of milking can be used;

- if poultry birds such as hens were used as the TGC host, then the eggs are collected and taken to the protein purification stage;

- processing of proteins from organs whose products cannot be externally accessed is achieved by obtaining the relevant organs, for which the animal must usually be killed, e.g. with fish;

- if the somatic transgenic tissue is blood, then the desired product is obtained after venous aspiration, from the blood or its cells and purified by methods familiar to the expert.

Example 10: Initial purification of the protein

Preliminary purification of the protein to be produced is achieved by separation processes, which are familiar to the expert as mainly physical or physico-chemical methods. Amongst these are precipitating the proteins using salts

(for example, ammonium sulphate), acids (for example, trichloroacetic acid) and using heat or cold.

A rough separation can also be achieved via column chromatography. All the methods used here strongly depend on the primary media in which the protein is enriched. For example, many methods are known for the processing of milk or eggs in industry, and they can be used in the invention described here. The same also applies to processing of blood as a somatic transgenic tissue. Here it is possible to refer to the experience of transfusion medicine, particularly the processing and purification of blood clotting factors.

Example 11: Purification of the protein

For the final purification of the proteins, all the methods used in conventional purification of proteins can be used. Amongst them are:

- purification using affinity chromatography, for example exploiting the receptor-ligand interaction;

- the preparation of fusion proteins with so-called "tags", which can be used for specific interaction with a matrix in chromatography (for example, polyhistidine tag and nickel column chromatography; the streptavidin-biotin technology of affinity purification). The tags can be then removed by appropriate introduction of a corresponding protease cutting site allowing subsequent release of the desired protein following protease digestion;

- purification via specific antibodies (immunoaffinity chromatography);

- the exploitation of natural affinities between the target protein and other proteins, carbohydrates or other binding partners, as in the case of toxin A of Clostridium difficile, which binds to thyroglobin at 4 °C and is subsequently eluted by raising the temperature to 37 °C.

Example 12: Production of TGC proteins:

The list of proteins which it is possible to produce with the TGC method is theoretically unlimited and above all includes the range of hormones, regulatory factors, enzymes, enzyme inhibitors and human monoclonal antibodies, as well as the production of surface proteins of pathogenic microorganisms or viral envelope proteins so as to safely produce diagnostic tests and vaccines which can be tolerated. The list covers high volume products such as human serum albumin and also proteins used in smaller quantities, such as hirudin, blood clotting factors, antigens for tumour prophylaxis and for active immunisation (for example, papilloma antigen) or for passive immunisation.

Bibliography

1. Cossart, P. and Finlay, B.B. "Exploitation of mammalian host cell functions by bacterial pathogens". Science 276: 718-725.

2. Falkow, S., Isberg, R.R. and Portnoy D.A. (1992). "The interaction of bacteria with mammalian cells". Ann. Rev. Cell Biol. 8: 333-63.

3. Weinberg, A.N., "Zoonoses", in Principle and Practice of Infectious Diseases. Eds. Mandell, Douglas and Bennett, J.E. and Dolin R., pp. 291-295. Churchill Livingstone, New York, 1995.

4. Farber, J.M. and Peterkin, P.J. (1991). "Listeria Monocytogenes - a foodborne pathogen". Microbiol. Rev. 55: 476-511.

5. Thoen, C.O. (1994). "Tuberculosis in wild and domestic animals", in Tuberculosis: Pathogenesis, Protection and Control, pp. 157-62. ASM, Washington DC 20005.

6. von Hase, U., Pulz, M., Windorfer, A. "EHEC in Niedersachsen, Januar 1995 - August 1997". Niedersächs. Ärztebl. (1997), pp. 20-23 and 38-40.

7. Swaminathan B., Rocourt J., and Bille J. (1995). "Listeria", in Manual of Clinical Microbiology. Eds Murray, P.R., Baron, E.J., Pfaller, M.A., Tenover, F.C., and Yolken, R.H., pp. 341-348. ASM Press, Washington DC,

8. Hof, H., Nichterlein, T., and Kretschmer, M. (1997). "Management of Listeriosis". Clin. Microbiol. Rev. 10: 345-357.

8a. Simon, S. and Stille, W., "Antibiotikatherapie". Schattauerverlag.

9. Chakraborty, T. and Wehland, J. (1997). "The host cell infected with Listeria monocytogenes", in Host Response to intracellular pathogens, pp. 271-290, Ed. S.H.E. Kaufmann R.G. Landes Co., Austin, USA.

10. Gaillard, J.L., Berche, P., Frehel, C., Gouin, E. and Cossart, P. (1991). "Entry of L.monocytogenes is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci". Cell, 65: 1127-1141.

11. Lingnau, A., Domann, E., Hudel, M., Bock, M., Nichterlein, T., Wehland, J. and Chakraborty, T. (1995). "Expression of inlA and inlB in L. monocytogenes EGD, whose products mediate bacterial entry into tissue culture cell lines, by PrfA-dependent and -independent mechanisms". Infect. Immun., 63: 3896-3903.

12. Alvarez-Dominguez, C., Carasco-Martin, E., and Levya-Cobian, F. (1993). "Role of comolement comopnenet Clq in phagocytosis of L. monocytogenes by murine macrophage-like cell lines". Infect. Immun., 61: 3664-3672.

13. Dunne, D.W., Resnick, D., Greenberg, J., Krieger, M., and Joiner, K.A. (1994) "The type I macrophage scavenger receptor binds to Gram-positive bacteria and recognizes lipoteicheoic acid". Proc. Natl. Acad. Sci. USA, 91: 1863-7.

14. Gaillard, J.-L., Berche, P., and Sansonetti, P.J. (1986). "Transposon mutagenesis as a tool to study the role of hemolysin in virulence of Listeria monocytogenes". Infect. Immun., 52: 50-55.

15. Theriot, J.A., Rosenblatt, J., Portnoy, D.A., Goldschmidt-Clermont, P.J., and Mitchison, T.J. (1994). "Involvement of profiling in the actin-based motility of Listeria monocytogenes in cells and cell-free extracts". Cell 76: 505-517.

16. Chakraborty, T., Ebel, F., Domann, E., Niebuhr, K., Gerstel, B., Pistor, S., Temm-Grove, C.J., Jockush, B.M., Reinhard, M., Walter, U., and Wehland, J. (1995). "A focal adhesion factor directly linking intracellularly motile Listeria monocytogenes and Listeria ivanovii to the actin-based cytoskelton of mammalian cells". EMBO J. 14: 1314-21.

17. Vazquez-Boland, J.A., Kocks, C., Dramsi, S., Ohayon, H., Goeffroy, C., Mengaud, J., and Cossart, P. (1992). "Nucleotide sequence of the lecithinase operon of L. monocytogenes and possible role of lecithinase in cell-to-cell spread". Infect. Immun. 60: 219-30.

18. L'Hopital, S.J., Marly, J., Pardon, P., and Berche, P. (1993). "Kinetics of antibody production against listeriolysin O in sheep with listeriosis". J. Clin. Microbiol. 31: 1537-40.

19. Domann, E., Zechel, S., Lingnau, A., Hain, T., Darji, A., Nichterlein, T., Wehland, J., and Chakraborty, T. (1997). "Identification and characterization of a novel PrfA-regulated gene in listeria monocytogenes whose product, IrpA, is highly homologous to internalin proteins, which contain leucine-rich repeats". Infect. Immun. 65: 101-9.

20. Grenningloh, R., Darji, A., Wehland, J., Chakraborty, T., and Weiss, S. (1997). "Listeriolysin and IrpA are major protein target of the human humoral response against Listeria monocytogenes". Infect. Immun. 65: 3976-3980, 1997.

21. Shen, H., Slifka, M.K., Matloubian, M., Jensen, E.R., Ahmed, R., and Miller, J.F. (1995). "Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity". Proc. Natl. Acad. Sci. USA 92: 3987-91.

22. Slifka, M.K., Shen, H., Matloubian, M., Jensen, E.R., Miller, J.F. and Ahmed, R. (1996). "Antiviral cytoxic T-cell memory by vaccination with recombinant Listeria monocytogenes". J. Virology 70: 2902-10.

23. Jensen, E.R., Selvakumar, R., Shen, H., Ahmed, R., Wettstein, F.O., and Miller, J.F. (1997). "Recombinant Listeria monocytogenes Vaccination Eliminates Papillomavirus-Induced Tumors and prevents Papilloma Formation from viral DNA". J. Virol. 71: 8467-8474.

24. Schafer, R., Portnoy, D.A., Brassell, S.A., and Paterson, Y. (1992). "Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine". J. Immunol. 149: 53-9.

25. Ikonomadis, G., Paterson, Y., Kos, F.J., and Portnoy, D.A., (1994). "Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes". J. Exp. Med. 180: 2209-18.

26. Frankel, F.R., Hegde, S., Lieberman, J., and Paterson, Y. (1995). "Induction of cell-mediated immune response to human immunodeficiency virus type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector". J. Immunol. 155: 4775-82.

27. Pan, Z.K., Ikonomidis, G., Lazenby, A., Pardoll, D., and Paterson, Y. (1995). "A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen

protects mice against lethal tumour cell challenge and causes regression of established tumours". Nature Med. 1: 471-7.

28. Dramai, S., Kocks, C., Forestier, C. and Cossart, P. (1993). "Internalin-mediated invasion of epithelial cells by L. Monocytogenes is regulated by bacterial growth, temperature and the pleiotropic activator, prfA". Mol. Microbiol. 9: 931-41.

29. Alvarex-Dominguez, C., Vazquez-Boland, J.A., Carrasco-Marin, E., Lopez-Mato, P. and Leyva-Cobian, F. (1997). "Host cell heparan sulfate proteoglycans mediate attachment and entry of Listeria monocytogenes, and the listerial surface protein ActA is involved in heparan sulfate receptor recognition". Infect. Immun. 65: 78-88.

30. Domann, E., Wehland, J., Rohde, M., Pistor, S., Hartl, M., Goebel, W., Leimeister-Wächter, M., Wuenscher, M., and Chakraborty, T. (1992). "A novel bacterial virulence gene in L. monocytogenes required for host microfilament interaction with homology to the proline rich region of vinculin". EMBO. J. 11: 1981-1990.

31. Kocks, C., Gouin, E., Tabouret, M., Berche, P., Ohayon, M., and Cossart, P. (1992). "Listeria monocytogenes induced actin assembly requires the act gene product, a surface protein". Cell 68: 521-31.

32. Armstrong, D., "Listeria monocytogenes" (1995) in Principle and Practice of Infectious Diseases, Eds. Mandell, Douglas and Bennett, J.E. and Dolin R., pp. 1880-1885. Churchill Livingstone, New York, 1995.

32a. Boucher, R.C. (1996). "Current status of CF gene therapy". Trends in Genetics 12: 81-84.

32b. Bank, A. (1996). "Human somatic cell gene therapy". BioEssays 18: 999-1007.

33. O'Callaghan, D., Maskell, d., Titi, J., Dougan, G. (1990). "Immune responses in BALB/ C mice following immunization with aromatic compound or purine-dependent Salmonella typhimuriium strains". Immunology 69: 184-189.

34. Tacket, C.O., Sztein, M.B., Losonsky, G.A., Wasserman, S.S, Nataro, J.P., Edelman, R., Pickard, D., Dougan, G., Chatfiled, S., and Levine, M.M. (1997). "Safety of Live Oral Salmonella typhi Vaccine Strains with deletions in htrA and aroC, aroD and immune response in humans". Infect. Immun. 65: 452-456.

35. Curtiss III, R. (1989). "Attenuated Salmonella strains as live vectors for the expression of foreign antigens". In New generation vaccines: The molecular approach (ed. M.M. Levine and G. Woodrow), p. 161. Marcel Dekker, New York.

36. Hopkins, S., Kraehenbuhl, J.-P., Schödel, F., Potts, A., Peterson, D., De Grandi, P. and Nardeli-Haeflinger, D. (1995). "A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization". Infect. Immun. 63: 3279-3286.

37. Berkmen, M., Benedik, M.J., and Blasi, U. (1997). "The Serratia marescens NucE protein functions as a holin in Escherichia coli". J. Bacterial. 179: 6522-6524.

38. Diaz, E., Munthali, M., de Lorenzo, V., and Timmis, K.N. (1994). "Universal barrier to lateral spread of specific genes among microorganisms". Mol. Microbiol. 13: 855-861.

39. Hohmann, El., Oletta, C.A., Loomis, W.P., and Miller, S.I. (1995). "Macrophage-inducible expression of a model

antigen in Salmonella typhimurium enhances immunogeneticity". Proc. Natl. Acad. Sci. USA 92: 2904-2908.

40. Park, S.F., and Stewart, G.S. (1990). "High-efficiency transformation of Listeria monocytogenes by electroporation of penicillin-treated cells". Gene 94: 129-132.

41. Premaratne, R.J., Lin, W.J., and Johnson, E.A. (1991), "Development of an improved chemically defined minimal medium for L. monocytogenes". Appl. Environ. Microbiol. 57: 3046-48.

CLAIMS

1. A TGC procedure for inducing targeted somatic transgenesis in an animal host, characterised in that bacteria with foreign DNA integrated into an episomal vector, under the control of eukaryotic regulatory elements for subsequent transcription and expression, release the said foreign gene in the host, in the case of infection of a whole organism, thus causing transcription and expression of foreign DNA and/ or foreign protein in said location.

2. The TGC method according to claim 1, characterised in that the bacteria release foreign genes in the case of infection of an organ through targeted perfusion or in culture, thus causing transcription and expression of foreign nucleic acid and/ or foreign protein in the organ.

3. The TGC method according to claim 1, characterised in that the bacteria release foreign genes in the case of infection of animal tissue, thus causing transcription and expression of foreign nucleic acid and/ or foreign protein in the tissue.

4. The TGC method according to claim 1, characterised in that the bacteria release foreign genes in the case of infection of a mixture of cells or a single cell line, thus causing transcription and expression of foreign nucleic acid and/ or foreign protein in the single cells of the mixture or in the cell line.

5. The TGC method according to claims 1 to 4, characterised in that the foreign DNA introduced into the host organism through bacterial infection causes the creation of a protein missing or foreign to the host organism in said location, or through creation of

single or double strand nucleic acid raises, lowers or prevents the creation of a protein or the effect of a nucleic acid in the host organism.

6. A method according to claim 5, characterised in that the foreign DNA introduced into the host organism through bacterial infection is used

a) for somatic gene therapy or

b) for immunological protection against microbial agents or

c) for immunological protection against tumour diseases

and has prophylactic or therapeutic effect.

7. The method according to claims 1 to 6, characterised in that bacteria are used of the types Aeromonads, Bartonella, Brucella, Campylobacter, Clostridia, Enterobacteriaceae, Legionella, Listeria, Mycobacterium, Renibacterium, Rhodococcus or other bacteria which are genetically or biochemically related to the said types and which are intracellularly viable in an eukaryotic host organism

8. The method according to claim 7, characterised in that bacteria, through selection and genetic manipulation of endogenous bacterial pathogenicity-associated genes, preferable have their in vivo pathogenicity weakened or strengthened in such a way that the bacteria penetrate

a) into defined organs of the whole organism,

b) into particular tissue of the host organism or

c) into particular compartments of cells

and release foreign DNA in said locations.

9. The method according to claim 8, characterised in that the said manipulated bacteria are Listeria.

10. The method according to claim 9, characterised in that the said manipulated bacteria are Listeria with the deposit numbers DSM 11881 and DSM 11882.

11. The method according to claims 9 and 10, characterised in that in the said bacteria, the genes of SEQ ID No. 1 and SEQ ID No. 2 named in the sequence protocol, or genes which correspond to them in at least 35 % of the nucleotide positions, are genetically mutated, deleted or blocked.

12. A bacterial strain for TGC method for inducing targeted somatic transgenesis, characterised in that within said bacterial strain, the foreign DNA integrated in the vector and prepared for subsequent transcription and expression, is under the control of regulatory elements which derive from the target organ to be infected or are directed for expression at this target organ.

13. The bacterial strain according to claim 12, characterised in that it has been mutated into a safety strain, which is by its growth no longer capable of adapting to environmental conditions as the result of a mutation in a gene (cspl mutant DSM 11883) and/ or being genetically altered through an auxotrophic mutation corresponding to SEQ 1 and/ or through a mutation in the sense of endogenous attentuation (strains DSM 11881 and 11882) and/ or

through additional equipping with exogenous suicide gene(s).

14. The bacterial strain according to claim 13, characterised in that it is mutated into a safety strain, in which

a) the cspl gene according to sequence protocol ID No. 2 or a gene with at least 35 % of the nucleotides in the same positions, is mutated or blocked or

b) the cpsl gene is deleted (strain DSM 11883),

c) the dapE gene according to sequence protocol SEQ ID No. 1 or a gene with at least 35 % of the nucleotides in the same positions, is deleted or blocked or

d) the actA gene and/ or the plcB gene and/ or the hly gene or other genes involved in virulence are mutated, deleted or blocked.

15. The method according to claim 8, characterised in that the said manipulated bacteria are Salmonella, particularly Salmonella of the strain with deposit number ATCC14028 or descendants of this strain which have been genetically altered according to claim 14.

16. The method according to claim 15, characterised in that the bacteria are auxotrophic through a mutation in the aroA gene, deposited in the Gene bank, Sequence M 10947.

17. The method according to claim 8, characterised in that the said genetically manipulated bacteria are apathogenic Listeria, apathogenic or optionally

pathogenic Enterobacteriaceae or other pathogenic bacteria.

18. The method for the transfection of animal cells by foreign DNA, characterised in that the bacteria, as carriers of the foreign DNA in the cytoplasm,

a) are not viable due to an auxotrophic mutation;

b) are not viable due to a foreign suicide gene;

c) penetrate into the endosomes of the cells, but cannot leave this compartment and are lysed in said location;

d) are taken up into phagolysosomes, lyse these compartments and penetrate into the cytoplasm; and

e) are destroyed by antibiotic treatment

and thereby release the foreign DNA.

19. A method for the production of a predetermined foreign protein, characterised in that a selected cell, a selected tissue or an organ is targeted for bacterial infection and the creation of predetermined protein is initiated in said location and after which the foreign protein is isolated from the cell, tissue or organ and is purified.

20. The method according to claim 20, characterised in that the expression of foreign protein in the udder of milk producing animals or in the eggs of poultry or in the blood or other tissue of farm animals is induced by infection with bacteria.

21. A transgenic farm animal characterised in that all the cells of its organism or the cells of one or more of its tissues or organs are genetically altered using a method according to claim 1.

22. The method for the induction of somatic transgenesis according to claim 3, characterised in that the somatic transgenic tissue is reimplanted in a whole organism and the living whole organism in this way becomes somatically transgenic.

ABSTRACT

Disclosed is a TGC method for inducting targeted somatic transgenesis in an animal host, whereby bacteria with a foreign DNA integrated into an episomal vector release, under the control of eukaryotic regulatory elements for ulterior transcription and expression, said foreign DNA in the case of infection of a foreign organism, organ, tissue, cell line or individual cells, causing transcription and expression of foreign DNA and/or foreign protein in said location.

SEQUENCE PROTOCOL

GENERAL INFORMATION

APPLICANTS: 1. Outside lecturer
Dr. Christoph von Eichel-Streiber
Bingerweg 15
55444 Schweppenhausen
Federal Republic of Germany
Tel.: 06724/33 98
Fax : 06724/33 98

2. Prof. Dr. Trinad Chakraborty
Seltersweg 85
35390 Gießen
Federal Republic of Germany
Tel.: 0641/76 536
Fax : 0641/99 41 259

DESCRIPTION OF THE INVENTION:

A TGC method for inducting targeted somatic transgenesis

NUMBER OF SEQUENCES: 2

POSTAL ADDRESS: Patent attorneys
Dr. Rainer A. Keil
Ludwig R. Schaafhausen
Nanno M. Lenz
Dr. K.-H. Meyer-Dulheuer
Eysseneckstraße 31
D-60322 Frankfurt am Main

COMPUTER-READABLE VERSION

DATA CARRIER: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC DOS/MS DOS
SOFTWARE: Word Perfect 6.0

Information on Sequence ID No. 1:

Length:	1260 base pairs
Type:	Nucleic acid and amino acid sequences derived from it
Strand form:	single strand
Topology:	linear
Origin:	Listeria monocytogenes strain EGD Serotype 1/2a
Feature:	Sequence of the dapE gene, which is one of the key enzymes needed for synthesis of diaminopimelic acid. The amino acid sequence is highly homologous to N-succinyl-L-diaminopimelic acid desuccinylase (dapE) from e.g. Escherichia coli, Bacillus subtilis, Lactobacillus spp., Mycobacterium tuberculosis.
Amino acid sequence:	318 amino acids
Nucleotide sequence:	1260 nucleotides

```
1     TGCCTTTATA GAGAACGGGA AAACATAGAG TGGAATTCAT AGAAAGAGGG
51    CGTGAAATAT GGACCAACAA AAAAAGATTC AAATTTTAAA GGACTTGGTA
101   AATATTGATT CGACTAATGG GCATGAAGAA CAAGTTGCGA ACTATTTGCA
151   AAAGTTGTTA GCTGAACATG GTATTGAGTC CGAAAAGGTA CAATACGACC
201   TAGACAGAGC TAGCCTAGTA AGCGAAATTG GTTCCAGTAA CGA GAA GGT T
                                                R   E   G
251   TG GCA TTT TCA GGG CAT ATG GAT GTA GTT GAT GCG GGT GAT GTA TCT AAG
      L   A   F   S   G   H   M   D   V   V   D   A   G   D   V   S   K -
301   TGG AAG TTC CCA CCT TTT GAA GCG ACA GAG CAT GAA GGG AAA CTA TAC GG
        W   K   F   P   P   F   E   A   T   E   H   E   G   K   L   Y   G -
351   A CGC GGC GCA ACG GAT ATG AAG TCA GGT CTA GCG GCG ATG GTT ATT GCA A
```

R G A T D M K S G L A A M V I A -

401 TG ATT GAA CTT CAT GAA GAA AAA CAA AAA CTA AAC GGC AAG ATC AGA TTA

M I E L H E E K Q K L N G K I R L -

451 TTA GCA ACA GTT GGG GAA GAG ATC GGT GAA CTT GGA GCA GAA CAA CTA AC

L A T V G E E I G E L G A E Q L T -

501 A CAA AAA GGT TAC GCA GAT GAT TTA CAT GGT TTA ATC ATC GGC GAA CCG A

Q K G Y A D D L H G L I I G E P -

551 GT GGA CAC AGA ATC GTT TAT GCG CAT AAA GGT TCC ATT AAT TAT CCC GTT

S G H R I V Y A H K G S I N Y P V -

601 AAA TCC ACT GGT AAA AAT GCC CAT AGT TCG ATG CCG GAA TCT GGT GTG AA

K S T G K N A H S S M P E S G V N -

651 T GCG ATT GAT AAC TTG CTG CTA TTT TAT AAT GAA GTA GAA AAA TTC GTG A

A I D N L L L F Y N E V E K F V -

701 AA TCA GTT GAT GCT ACT AAC GAA ATA TTA GGC GAT TTT ATT CAT AAT GTC

K S V D A T N E I L G D F I H N V

751 ACC GTA ATT GAT GGT GGA AAT CAA GTC AAT AGT ATC CCT GAA AAA GCA CA

T V I D G G N Q V N S I P E K A Q -

801 A CTG CAA GGG AAT ATT CGC TCG ATT CCA GAA ATG GAT AAT GAA ACA GTG A

L Q G N I R S I P E M D N E T V -

851 AA CAA GTG CTA GTG AAG ATT ATC AAT AAG TTA AAC AAA CAG GAA AAT GTG

K Q V L V K I I N K L N K Q E N V -

901 AAT CTG GAA TTA ATA TTT GAT TAT GAT AAA CAA CCA GTA TTT AGT GAT AA

N L E L I F D Y D K Q P V F S D K -

951 A AAT TCG GAT TTA GTC CAC ATT GCT AAG AGC GTA GCA AGC GAC ATT GTC

N S D L V H I A K S V A S D I V

1001 AAA GAA GAA ATC CCA TTA CTC GGT ATT TCC GGA ACA ACC GAT GCA GCA GA

K E E I P L L G I S G T T D A A E -

1051 A TTT ACC AAA GCT AAG AAA GAG TTC CCA GTG ATT ATT TTT GGA CCA GGA A

F T K A K K E F P V I I F G G G -

1101 AC GAA ACC CCT CAC CAA GTA AAC GAA AAT GTT TCT ATA GGA AAT TAT TTG

N E T P H Q V N E N V S I G N Y L -

1151 GAG ATG GTA GAT GTT TAC AAA CGG ATT GCC ACC GAG TTT TTA TCT TGA TGA

E M V D V Y K R I A T E F L S STOP

1201 AACTTTAACT TTACTTATTT CCCGATATAA AATAAGTAAT TAATAGAAGT

1251 CTAGTATTTG 1260

Information on Sequence ID No. 2:

Length:	1337 base pairs
Type:	Nucleic acid and amino acid sequences derived from it
Strand form:	single strand
Topology:	linear
Origin:	Listeria monocytogenes strain EGD 1/2a
Feature:	Sequence of the "cold shock protein" cspl; this protein is essential for the viability of Listeria at low temperatures.

Amino acid sequence:	66 amino acids
Nucleotide sequence:	1337 nucleotides

```
1     GAGGCAAGTG GACTAATCAT AAAGTTTTTG GCGATGCAAC TGCGTTTTG
51    GCAGGAGATG CTTTACTAAC GCTCGCTTTT TCTATTTTAG CTGAAGACGA
101   TAATTTATCT TTTGAGACAC GCATTGCTTT GATTAACCAA ATTAGTTTTA
151   GTAGCGGTGC AGAAGGAATG GTTGGTGGTC AACTTGCAGA CTTGGAAGCG
201   GAAAACAAAC AAGTGACGCT AGAAGAGTTA TCATCCATTC ATGCACGAAA
251   AACGGGTGAA TTATTAATTT ATGCTGTAAC CTCTGCAGCA AAAATTGCGG
301   AAGCTGATCC AGAACAAACG AAACGCTTAC GAATTTTTGC AGAGAATATT
351   GGGATTGGAT TTCAAATTAG CGACGATATT TTAGATGTAA TTGGTGATGA
401   AACGAAAATG GGTAAAAAGA CAGGGGCCGA CGCTTTTCTG AATAAAAGTA
451   CCTATCCCGG ATTACTCACG CTTGATGGGG CAAAAAGGGC ATTAAATGAG
501   CATGTTACGA TTGCAAAGTC AGCGCTTTGA GGGCATGATT TCGATGATGA
551   AATTCTCTTG AAACTTGCTG ATTTAATCGC ACTTAGAGAA AATTAATCAT
601   AATTATCTAG TAATTTCAAA ATTTTTTCAC ATATATAATT CAAATTGATT
651   TGCTTTTCCT AAAATACCGT GTTATACTAA TGTAAGATTA TTTTTGTGGG
701   TGAAAGATAC GATTGTGAAC AACTTTCCAT CTCGTGCCGT TAAGCAAGAA
751   TAGTAAATAA TTAGTGTGCA TAACACACGA GGAGGAACAT GAAC ATG GAA
                                                     M   E

801   CAA GGT ACA GTA AAA TGG TTT AAC GCA GAA AAA GGA TTT GGT TTT ATC GA
       Q   G   T   V   K   W   F   N   A   E   K   G   F   G   F   I   E
851   A CGC GAA AAC GGT GAC GAT GTA TTC GTA CAT TTC AGC GCT ATC CAA GGC G
```

```
                R   E   N   G   D   D   V   F   V   H   F   S   A   I   Q   G
901   AC GGA TTC AAA TCT TTA GAC GAA GGT CAA GCA GTA ACT TTC GAC GTT GAA
          D   G   F   K   S   L   D   E   G   Q   A   V   T   F   D   V   E
951   GAA GGC CAA CGC GGA CCT CAA GCA GCT AAC GTT CAA AAA GCG TAA TTC TA
            E   G   Q   R   G   P   Q   A   A   N   V   Q   K   A STOP
1001  TTTTTTGAAT AAGAAAAAGC AAATCATTTC GGTGATTTGC TTTTTTATTT
1051  GTCTAAAATT ATTTTACCTT GTTTGGTTTA ATGGCGATTG TTTGCTATAA
1101  TAAGAACAAT TAATCGAGAA AAAAGACCTT GCACGCATTC ATGCGAGTGG
1151  CTCTTTGGAA AGTGAGTTGT TTTTATTTGG ATCTTTTAAA GATAAAGGAT
1201  CCTTCCTTTA TGAAGCGATT GGATATACAA GAATTAGAAG CACTTGCAGC
1251  GGATATTCGC GCTTTTTTAA TTACTTCTAC ATCTAAATCA GGTGGGCATA
1301  TTGGTCCGAA TCTTGGTGTG GTAGAACTAA CGATTGC
```

Docket No.: 113.1007

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:
My residence, post office address and citizenship are as stated below next to my name.
I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TGC METHOD FOR INDUCTING TARGETED SOMATIC TRANSGENESIS, the specification of which (check one)

___ is attached hereto
X was filed on December 11, 1998 as International Application Serial No. PCT/EP98/08096
and was amended on _____ (if applicable).
___ I hereby authorize and request our attorney, Davidson, Davidson & Kappel, LLC, of 1140 Avenue of the Americas, New York, New York 10036 to insert here in parentheses (Application number _____, filed _____) the filing date and application number of said application when known.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.
I acknowledge the duty to disclose all information which is known to me to be material to the patentability of this application as defined in Title 37, Code of Federal Regulations, §1.56.
I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign and/or provisional application(s) for patent or inventor's certificate listed below and have also identified below any foreign and/or provisional application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR APPLICATION(S)			Priority claimed	
197 54 938.1 (Number)	Germany (Country)	11/12/97 (Day/Month/Year Filed)	X Yes	___ No
_____ (Number)	_____ (Country)	_____ (Day/Month/Year Filed)	___ Yes	___ No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial Number)	(Filing Date)	(Status) (patented, pending, abandoned)
_____	_____	_____
_____	_____	_____

And I hereby appoint Clifford M. Davidson, Registration No. 32,728, Leslye B. Davidson, Registration No. 38,854, Cary S. Kappel, Registration No. 36,561, William C. Gehris, Registration No. 38,156, Julie L. Bowker, Registration No. 37,870, Robert J. Paradiso, Registration No. 41,240, Scott L. Appelbaum, Registration No. 41,587, Cynthia R. Moore, Registration No. 46,086 and David Knasiak, Registration No. 45,991 my attorneys, with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith; correspondence address: DAVIDSON, DAVIDSON & KAPPEL, LLC, 1140 Avenue of the Americas, 15th Floor, New York, New York 10036; Telephone: (212) 997-1028; Fax: (212) 997-1037.
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first Inventor: Christoph VON EICHEL-STREIBER
Inventor's signature: _____
Date: 24/5/00
Residence: Schweppenhausen, Germany DEX
Citizenship: German
Post Office Address: Bingerweg 15, D-55444 Schweppenhausen, Germany

Full name of joint Inventor, if any: Trinad CHAKRABORTY
Second Inventor's signature: _____
Date: 24/5/2000
Residence: Giessen, Germany DEX
Citizenship: ~~German~~ SINGAPOREAN
Post Office Address: Selterweg 85, D-35390 Giessen, Germany

Full name of joint Inventor, if any: _____
Third Inventor's signature: _____
Date: _____
Residence (city) _____, (state or country) _____
Citizenship: _____
Post Office Address: _____

Full name of joint Inventor, if any: _____
Fourth Inventor's signature: _____
Date: _____
Residence (city) _____, (state or country) _____
Citizenship: _____
Post Office Address: _____